



University of Dundee

Mechanistic and Structural Features of PROTAC Ternary Complexes

Casement, Ryan; Bond, Adam; Craigon, Conner; Ciulli, Alessio

Published in:
Targeted Protein Degradation

DOI:
[10.1007/978-1-0716-1665-9_5](https://doi.org/10.1007/978-1-0716-1665-9_5)

Publication date:
2021

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Casement, R., Bond, A., Craigon, C., & Ciulli, A. (2021). Mechanistic and Structural Features of PROTAC Ternary Complexes. In A. M. Cacace, C. M. Hickey, & M. Békés (Eds.), *Targeted Protein Degradation: Methods and Protocols* (1 ed., pp. 79-113). (Methods in Molecular Biology; Vol. 2365). Humana Press. https://doi.org/10.1007/978-1-0716-1665-9_5

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Metadata of the chapter that will be visualized online

Chapter Title	Mechanistic and Structural Features of PROTAC Ternary Complexes
Copyright Year	2021
Copyright Holder	Springer Science+Business Media, LLC, part of Springer Nature
Author	Family Name Casement Particle Given Name Ryan Suffix Division Division of Biological Chemistry and Drug Discovery, School of Life Sciences Organization University of Dundee Address Dundee, Scotland, UK
Author	Family Name Bond Particle Given Name Adam Suffix Division Division of Biological Chemistry and Drug Discovery, School of Life Sciences Organization University of Dundee Address Dundee, Scotland, UK
Author	Family Name Craigon Particle Given Name Conner Suffix Division Division of Biological Chemistry and Drug Discovery, School of Life Sciences Organization University of Dundee Address Dundee, Scotland, UK
Corresponding Author	Family Name Ciulli Particle Given Name Alessio Suffix Division Division of Biological Chemistry and Drug Discovery, School of Life Sciences Organization University of Dundee Address Dundee, Scotland, UK Email a.ciulli@dundee.ac.uk
Abstract	The rapid and ever-growing advancements from within the field of proteolysis-targeting chimeras (PROTAC)-induced protein degradation

have driven considerable development to gain a deeper understanding of their mode of action. The ternary complex formed by PROTACs with their target protein and E3 ubiquitin ligase is the key species in their substoichiometric catalytic mechanism. Here, we describe the theoretical framework that underpins ternary complexes, including a current understanding of the three-component binding model, cooperativity, hook effect and structural considerations. We discuss in detail the biophysical methods used to interrogate ternary complex formation in vitro, including X-ray crystallography, AlphaLISA, FRET, FP, ITC and SPR. Finally, we provide detailed ITC methods and discuss approaches to assess binary and ternary target engagement, target ubiquitination and degradation that can be used to obtain a more holistic understanding of the mode of action within a cellular environment.

Keywords (separated by '-')	Targeted protein degradation (TPD) - proteolysis-targeting chimeras (PROTACs) - E3 ubiquitin ligase - Ternary complex - Hook effect - Cooperativity - Biophysical methods, crystal structures - Target engagement - Protein ubiquitination
--------------------------------	--

Mechanistic and Structural Features of PROTAC Ternary Complexes

2 AU1

3

Ryan Casement, Adam Bond, Conner Craigon, and Alessio Ciulli

4

Abstract

5

The rapid and ever-growing advancements from within the field of proteolysis-targeting chimeras (PROTAC)-induced protein degradation have driven considerable development to gain a deeper understanding of their mode of action. The ternary complex formed by PROTACs with their target protein and E3 ubiquitin ligase is the key species in their substoichiometric catalytic mechanism. Here, we describe the theoretical framework that underpins ternary complexes, including a current understanding of the three-component binding model, cooperativity, hook effect and structural considerations. We discuss in detail the biophysical methods used to interrogate ternary complex formation in vitro, including X-ray crystallography, AlphaLISA, FRET, FP, ITC and SPR. Finally, we provide detailed ITC methods and discuss approaches to assess binary and ternary target engagement, target ubiquitination and degradation that can be used to obtain a more holistic understanding of the mode of action within a cellular environment.

Key words Targeted protein degradation (TPD), proteolysis-targeting chimeras (PROTACs), E3 ubiquitin ligase, Ternary complex, Hook effect, Cooperativity, Biophysical methods, crystal structures, Target engagement, Protein ubiquitination

16

17

18

19

1 PROTAC Ternary Complexes: Equilibria and Crystal Structures

20

1.1 Two-Component vs. Three-Component Binding Models

21 AU2

22

23

24

25

26

Two-body binding equilibria have classically been addressed by the Hill–Langmuir equation which was formulated by Archibald Hill in 1910 to describe the interaction of oxygen with haemoglobin [1]. Since then, the sigmoidal dose–response curve which describes these systems has become a permanent fixture in drug discovery for the evaluation of ligands interacting with proteins.

As new chemical biology modalities such as bispecific antibodies [2], bivalent inhibitors [3–5], molecular glues [6] and most recently proteolysis-targeting chimeras (PROTACs) [7] have come to the fore, there is now an increased need to understand three-

27

28

29

30

Ryan Casement, Adam Bond and Conner Craigon contributed equally to this work.




Fig. 1 Comparison of binary and ternary complex formation. (a) Simulated dose–response curves using the Hill–Langmuir equation where increasing potency results in a left shift of the sigmoidal dose–response curve. (b) Depiction of bell-shaped dose–response curves typical in ternary complex formation. Increased cooperativity of a system results in improved ternary complex formation and heightening and widening of the curve. (c) Depiction of potential binding cycle of PROTAC-induced ternary complexes adapted from PDB 5T35. PROTAC shown as a red and blue surface joined by a linker, the PROTAC can either bind protein ‘A’ (pink surface) or protein ‘B’ first and cooperativity (α) can be calculated from the K_d values from the individual steps

component binding models and the characteristics of the ternary 31
 complex formed (Fig. 1). Bivalent modalities can be visualised 32
 to form a ternary complex in a two-step process as depicted in Fig. 1c. 33
 In the case of PROTACs, the binding order here could potentially 34
 be random, while molecular glues such as immunomodulatory 35
 imine drugs (IMiDs) have been shown to require binding to a 36
 specific protein (Cereblon or CRBN) before neo-substrates can 37
 be recruited [8]. Unlike the classical sigmoidal curve which is 38
 used to describe many two-body systems (Fig. 1a), the binding 39
 isotherm describing the formation of ternary complexes is usually 40
 represented by a bell-shaped curve (Fig. 1b). The first half of the 41
 isotherm is visually similar to that of a binary system until the point 42
 of saturation after which increasing ligand concentration will eventually 43
 decrease ternary complex concentration, a phenomenon 44

commonly known as the hook effect [9]. In addition, a further layer of complexity is added by potential interactions between the two protein-binding partners, resulting in cooperativity effects which essentially delineates ternary and binary binding affinities and modulates the height and width of the curve [10].

1.2 Cooperativity and the Hook Effect

The hook effect describes the declining effectiveness of a bifunctional molecule in forming a ternary complex at high concentrations due to the preferential formation of multiple binary complexes. This effect was observed as early as 1905 when the presence of a bell-shaped curve in immunoprecipitation assays was said to be caused by the ‘prozone phenomenon’ [11]. As well as causing issues in immune assays, the hook effect essentially limits the therapeutic window of potential therapeutics. This ‘dose-limited activity’ has been shown in monoclonal antibody therapies which operate via antibody-dependent cell-mediated cytotoxicity (ADCC) [12]. PROTAC’s hook effect was observed following western blotting, with the loss of protein degradation at high compound concentrations [13]. It was later observed biophysically, with the appearance of bell-shaped curves in the amplified luminescent proximity homogeneous assays (AlphaScreen or AlphaLISA) measuring ternary complex formation [14, 15]. One interesting observation is that not all PROTACs ‘hook’ equally potentially due to cooperativity effects as it has been shown that the hook effect can be attenuated by cooperativity [16].

PROTACs mode of action strictly depends on the formation of a ternary complex that is productive to subsequent target ubiquitination and degradation. This can be achieved in principle in a substoichiometric fashion (i.e. without the need to occupy in full the target protein) and via a catalytic cycle (i.e. the same molecule of PROTAC can deliver multiple cycles of protein ubiquitination and degradation). These features are predicted to drive potent target degradation activities at low PROTAC concentration and therefore in the first instance should correlate linearly with the amount of ternary complex. It is therefore important to better understand ternary complex formation equilibria and how they impact PROTAC mode of action (Fig. 1).

In the context of ternary complex formation, cooperativity (α) describes the increased affinity a ligand ‘B’ has for ‘Protein A’ in the presence of ‘Protein C’ vs. ‘Protein A’ alone. For PROTACs, A and C are usually different with one being an E3 ligase, but they could be the same species in the case of homo-PROTACs that dimerise an E3 ligase for self-degradation [17, 18]. Positive α values describe a cooperative system which favours the formation of the ternary complex and in the context of a bell-shaped curve (Fig. 1) essentially heightens and widens the curve, extending the activity range of any potential therapeutic. One prominent example of cooperativity from nature comes from bacterial superantigens. These are

bacterial toxins which exert their effect by binding major histocompatibility complex (MHC) class II molecules and T-cell receptors (TCR) to form a ternary complex, cross-linking T cells with antigen-presenting cells and resulting in a cytokine storm [19]. This interaction has been found to be highly cooperative by surface plasmon resonance (SPR) [20].

Molecular glues by definition cause the formation of stable ternary complexes often overcoming weak binary binding affinities and as such rely heavily on cooperativity for their activity. Examples include natural products such as rapamycin and the plant hormone auxin which highlights the structural diversity of molecular glues [21, 22]. While the 31-membered macrocycle rapamycin has a molecular weight of 914 Da and a total of 15 stereocentres, auxin (Indole-3-acetic acid) has a molecular weight of only 175 Da. Rapamycin which is approved as an immunosuppressant for organ transplant patients forms a ternary complex with FK506 binding protein (FKBP) and the FRB binding domain of the molecular target of rapamycin (mTOR) resulting in potent mTOR inhibition [21]. In a thorough biophysical characterisation of this complex, it was found that rapamycin binds to FRB with a 2000-fold improved binding affinity in the presence of FKBP [23]. Auxin functions as a plant hormone via binding to TIR1 and the subsequent recruitment of neo-substrates such as members of the Aux/IAA protein family. As TIR1 is the substrate receptor of a SCF E3 ligase, this interaction results in the proteasomal degradation of Aux/IAAs and effectively activates transcription of auxin response factor (ARF) proteins [22].

In addition to natural products, there are examples of synthetic molecular glues such as Indisulam and Thalidomide which were developed before their gluing activity was fully understood. These therapeutics recruit neo-substrates to the E3 ligases DCAF15 and CRBN, respectively (Fig. 2), resulting in proteasomal degradation [6]. CRBN-binding compounds (also known as IMiDs) have been shown to recruit and degrade a range of β -hairpin-containing proteins, for example zinc-finger proteins (Fig. 2a) [24]. Indisulam has been shown to degrade a specific protein, an essential mRNA splicing factor RBM39 [25, 26], and form a highly cooperative ternary complex with RBM39 and DCAF15 (Fig. 2b) [27]. In contrast to IMiDs and indisulam, PROTACs can either be cooperative or noncooperative facilitated by the fact they are bifunctional molecules and generally contain two already potent inhibitors linked together in some way. Just as cooperativity facilitates the activity of molecular glues (with often weak binary affinities) and can improve the degradation efficiency of PROTACs [14, 17, 28], the absence of positive cooperativity can still lead to potent degradation [29, 30].

The distinction between PROTACs and molecular glues which recruit E3 ligases is well-understood in chemical terms: PROTACs




Fig. 2 Comparison of binary and ternary complex formation. **(a)** Depiction of IMiD-based molecular glues Pomalidomide (left) and Lenalidomide (right) which recruit distinct neo-substrates SALL4 and CK1 α , respectively, among others. A requirement for neo-substrate recruitment to IMiD is a β hairpin loop which acts as a degron motif. **(b)** Structural basis for RCM39 recruitment to DCAF15 by Indisulam. Top left: full protein complex; top right: RBM39 is hidden to reveal Indisulam which is buried under RBM39 at the interface between it and DCAF15

are bifunctional molecules containing a linker, whereas molecular glues are essentially linker-less PROTACs and lack a target binding moiety. On the other hand, care needs to be taken when developing PROTACs made of E3 ligase binders that are themselves molecular glues, to ascertain the spectrum of potential proteins being degraded. This has been demonstrated by Yang et al. during the development of CRBN-based MDM2 degraders when they identified compound MG-277 which exhibited a high potency in phenotypic cancer cell growth assays despite showing only modest degradation of MDM2 [31]. It was found that the phenotypic activity of the compound was MDM2-independent and was a result of GSPT1 degradation which has also been identified as an off-target of some kinase degraders [32].

1.3 Structural Basis for PROTAC Cooperativity and Selectivity

In much of the early PROTAC literature, the nature of the ternary complex was often depicted as two proteins held spatially apart by a molecule with a linker ‘floating’ in empty space. This picture changed considerably with the emergence of the first structural

141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158

information on PROTAC-induced ternary complexes. In 2017, the structure solution of the BET bromodomain degrader MZ1 in complex with BRD4^{BD2} and VBC (VHL:ElonginB:ElonginC) helped establish a new model for PROTAC-induced ternary complexes [14]. Rather than acting as an inert spacer between the two independent ligands, the linker it was found to coil around itself, aiding formation of a significant protein–protein interaction (PPI) network and a bowl-shaped interface. These de novo PPIs resulted in a stable and cooperative ternary complex ($\alpha = 17.6$) demonstrated by isothermal titration calorimetry (ITC). Perhaps, most interesting was the fact that high cooperativity was not conserved across the BET family proteins, explaining the propensity for MZ1 to preferentially degrade BRD4 over the other bromodomains despite using a pan-BET inhibitor scaffold JQ1 [33]. This was a striking early example of the potential for PROTACs to impact drug discovery. The design of selective BET inhibitors had been challenging the field for years due to the highly conserved acetyllysine binding pocket [34]. By targeting the protein for degradation, the protein surface residues (which are typically much less conserved across protein families) were able to facilitate selectivity by forming de novo PPIs with the E3 ligase. The increased selectivity conferred by PROTAC-mediated degradation has also been demonstrated with the use of VHL and CRBN-recruiting PROTACs based on Foretinib, a nonselective c-MET tyrosine kinase inhibitor [15]. Despite retaining binding to a common set of 51 kinases, the compounds showed vastly different proteome-wide activity, and degradation activity was not found to correlate with binary affinities. In particular, one of the kinase targets (p38alpha) was shown to be effectively degraded in spite of a weak binary binding affinity for the kinase itself.

While these early studies shed light on the thermodynamic and structural properties of PROTAC-induced ternary complexes, it was not until 2019 that the first kinetic studies as evaluated by SPR were published [35]. With the VBC protein complex immobilised on the sensor chip surface Roy et al. studied, the binary and ternary half-lives ($t_{1/2}$) of previously published BET degraders including MZ1. Consistent with the previously discussed thermodynamic data, BRD4^{BD2}:MZ1:VBC was shown to form a remarkably stable ternary complex with a $t_{1/2}$ of 130 s compared to the binary (MZ1:VBC) value of 43 s. In addition, cooperativity values were calculated in these experiments which were found to correlate well to previously reported ITC values [14, 28]. This work was further validated later that year when the kinetic findings with MZ1 were independently repeated, along with the characterisation of the potent BET degrader GNE-987 which was shown to form an extremely long-lived complex with VBC and BRD4^{BD1} [36].

Although cooperativity is not a requirement for potent degradation, it can not only facilitate selectivity but also potentially allow

the use of weak ligands. This would potentially allow the degradation of ‘undruggable’ targets for which only weak ligands exist due to their shallow featureless pockets. If a PROTAC is able to induce productive PPIs and form a cooperative stable ternary complex, these proteins could be targeted; however, it is currently very difficult to predict features which will facilitate this cooperativity. It has been shown in the literature that this is possible. One of the first examples of degradation with a weak E3 ligase ligand was using a PROTAC containing a fluoro-hydroxyproline motif in the VHL binding ligand [37]. Despite the fluorinated VHL binding ligand 14b losing over 20-fold binding affinity with a dissociation constant (K_d) of 3 μM , when conjugated into a ‘MZ1-like’ PROTAC, it displayed a BRD4 DC_{50} between 10 and 30 nM likely owing to the measured high cooperativity ($\alpha = 14.5$) [37].

In a more recent study, the effect of using weaker VHL ligands in androgen receptor (AR) degraders was evaluated, working back from an already potent degrader [38]. In this case, a set of intentionally weaker VHL ligands were synthesised to obtain ligands with a K_i of 1–3 μM and conjugated to a previously optimised AR warhead-linker combination. Following degradation studies, it was found all the compounds tested could catalyse the degradation of AR protein and further linker optimisation afforded compound ARD-266 which reduces AR protein by >90% at 10 nM.

Both of the examples described imply that weak binary affinity can be compensated for, following PROTAC conjugation, likely due to the formation of a stable and cooperative ternary complex. While this is encouraging for potentially undruggable targets, these cases benefitted from being able to work backwards from an already potent degrader and the knowledge that the system being studied was ‘degradable’. In contrast, the prospect of starting with a weak ligand against a difficult target is expected to be challenging but is also one of the most exciting opportunities that a PROTAC approach offers.

1.4 Ternary Complex Structures to Guide PROTAC Design

The ability to generate structural information of PROTAC-induced ternary complexes opens the door for structure-based PROTAC design (SBPD) (Fig. 3). Just as structure-based drug design revolutionised drug discovery, SBPD is expected to aid the currently highly empirical nature of PROTAC design and optimisation. Rather than considering each ligand in isolation, structural information supported by molecular modelling tools allows for optimisation at the PPI interface especially through linker design.

The BRD4^{BD2}MZ1:VBC ternary complex structure discussed previously directly facilitated the rational design of novel PROTACs AT1 and MacroPROTAC-1 (Fig. 3a–c) [14, 39]. As the first published example of SBPD, AT1 was designed based on the MZ1 crystal structure which identified the *tert*-leucine group of the VHL warhead as an ideal linkage point that was hypothesised to




Fig. 3 Structure-based PROTAC design strategies. **(a)** Depiction of design strategies based on the MZ1 ternary crystal structure (PDB: 5T35). **(b)** Ternary crystal structure of MacroPROTAC1 bound to BRD4BD2 and VBC (PDB: 6SIS). **(c)** Chemical structures of the compounds described. **(d)** Ternary crystal structure of PROTAC1 bound to VBC and SMARCA2 (PDB: 6HAY) in which the linker adopts an unfavourable conformation and is pushed against the protein–protein interface. **(e)** Ternary crystal structure of the more potent PROTAC 2 bound to VBC and SMARCA2 (PDB: 6HAX); the more rigid linker now adopts a favourable conformation and forms a T-stacking interaction with Y98VHL. **(f)** Overlay of bioactive conformations PROTAC1 and PROTAC2 is depicted which reveals a good overall conservation of binding mode. Chemical structure of ACB11, the final optimised PROTAC which differs from PROTAC2 by a single additional oxygen atom in the linker (red)

AU3

better discriminate against the crystallographic binding mode and potentially increase selectivity. Following western blotting and unbiased proteomics AT1 was found to exhibit superior selectivity for BRD4 than MZ1 and still retain degradation potency on the face of a fivefold loss of binding affinity at VHL [14]. While the design of MacroPROTAC-1 was based on the same ternary crystal structure, a unique macrocyclisation strategy, supported by in silico calculations, was undertaken in order to lock the PROTAC in the crystallographically observed conformation. Macrocyclisation has been used as a strategy in drug discovery to increase potency and selectivity by reducing the entropic penalty for binding [40]. In the context of a PROTAC with a highly flexible linker, it was hypothesised that locking the PROTAC in its bioactive conformation could be a powerful strategy. In this study, the optimal macrocyclisation

255
256
257
258
259
260
261
262
263
264
265
266
267
268

vector and length were predicted computationally, an important step due to the bespoke linker synthesis that was required. Despite a 12-fold loss in binary binding affinity for BRD4^{BD2}, MacroPROTAC-1 exhibited comparable degradation activity to MZ1 and the ternary crystal structure confirmed the predicted binding mode (Fig. 3b) [39].

The examples discussed already have been based on the ternary structure of MZ1, a potent and already well-characterised degrader. Structural information has also been leveraged to drive the design of potent PROTACs for SMARCA2 and SMARCA4 proteins [41]. These are subunits of chromatin remodelling BAF/PBAF complexes which have been identified as cancer targets [41]. Although ligands exist for the bromodomains of these proteins, they have been shown to be ineffective as a cancer therapy [42]. In this study, an initial set of PROTACs was synthesised based on a published SMARCA2/4 bromodomain ligand [43] and a potent VHL-recruiting ligand [44]. Despite only partial degradation being observed, biophysical studies were crucial in identifying the most cooperative ligand PROTAC 1 which was co-crystallised with SMARCA2^{BD} and VBC. Inspection of the crystal structure revealed favourable PPIs between SMARCA2^{BD} and VBC; however, it was also observed that the polar polyethylene glycol linker was in a strained conformation and in unfavourable contacts with a hydrophobic interface within the complex (Fig. 3d). Armed with this information, a more lipophilic and rigid linker was designed containing a phenyl ring which could potentially form pi-stacking interactions at the interface. This led to the synthesis of PROTAC 2 and finally ACBII following further modification. The ternary crystal structure of PROTAC 2 revealed a similar binding mode of the initial hit and a T-stacking interaction between the linker and Y98 of VHL (Fig. 3e). These compounds displayed significantly improved degradation and were found to be highly cooperative and following proteomics studies ACBII was qualified as a potent and selective degrader of SMARCA2, SMARCA4 and PBRM1.

As a result of these important studies, the PROTAC ternary complex is now receiving increased attention within the field. Its characteristics in terms of cooperativity, stability, kinetics and potentially geometry have direct implications for selectivity and potency of target degradation. Currently, PROTAC design is largely empirical in nature, and due to the large number of variables including protein-binding warheads, linkage vectors and the chemical makeup of the linkers themselves, this creates a combinatorially large number of potential PROTACs for synthesis. With all this in mind, being able to measure biophysical parameters and generate structural information is deemed crucial for a guided design, possibly aided by molecular modelling efforts and consequently a much smaller synthesis workload and increased chances of success.

2 Characterisation of Ternary Complexes Using Biophysical Methods

317

The growing realisation of the important role of the ternary complex in the PROTAC mechanism of action has fuelled the development of new methods or the implementation of existing ones into characterising biophysically PROTAC ternary complexes as a crucial step to evaluate and understand their biological activity. Several biophysical methods have been developed to interrogate PROTAC-induced ternary complex formation both structurally, thermodynamically and kinetically.

2.1 X-Ray Crystallography

X-ray crystallography is a prominent tool in drug discovery to elucidate key structural insights into the binding modes between a small-molecule inhibitor and its target protein. However, crystallographic evidence of the target:PROTAC:E3 ligase long-remained elusive until the first ternary complex crystal structure was solved by Gadd et al. in 2017, as previously described (Fig. 3a) [14].

The methods Gadd et al. used to gain the ternary complex crystal structure of VCB:MZ1:Brd4^{BD2} were to first mix each component, VCB, MZ1 and Brd4^{BD2} in a 1:1:1 stoichiometric ratio to form a ternary complex with final combined concentration of 10 mg/mL. Crystals were then grown using a hanging-drop diffusion format by mixing equal volumes of the ternary complex solution and their crystallisation solution which comprised of 13% (w/v) PEG 8000 precipitating agent and a 0.1 M sodium citrate (pH 6.3) buffer [14]. Similar methods have been used more recently by Testa et al. to elucidate the ternary complex crystal structure of an MZ1 inspired, macrocyclic-PROTAC (Fig. 3b, c) [39], and by Farnaby et al. to crystallise VCB:PROTAC:SMARCA2^{BD} (Fig. 3d-f) [41].

As an additional step in the process, size exclusion gel filtration can be used to purify the ternary complex and separate it from any residual binary complexes and uncomplexed species. However, care should be taken in that the complex is sufficiently stable and not to dissociate significantly during the chromatographic run.

2.2 Proximity Binding Assays

Interrogation of ternary complex formation by proximity-based assays such as amplified luminescent proximity homogeneous assay (AlphaScreen/LISA) and time-resolved fluorescent resonance energy transfer (TR-FRET) provides a high-throughput method of measuring ternary complex formation. Both techniques share a similarity in that they require a donor and an acceptor species. When the donor species is excited by light and brought into close proximity of the acceptor, energy is transferred and light of a particular wavelength is emitted (Fig. 4a). The closer the two counterparts are brought together, the higher and more intense the output signal will be [45–47].




Fig. 4 Schematic representations of proximity-based assays. (a) Depiction of an AlphaLISA proximity-based assay. POI-1 and POI-2 are bound to a donor and an acceptor bead, respectively. Fluorescence of wavelength 520–620 nm is emitted as donor and acceptor are brought into close proximity via a PROTAC-induced ternary complex. (b) Bell-shaped curve produced from an AlphaLISA assay. As the concentration of PROTAC increases, more ternary complexes form, causing an increase in signal intensity. A decrease of signal is observed due to the characteristic hook effect. Positively cooperative (blue), non-cooperative (red) and negatively cooperative (green) ternary complex proximity profiles are highlighted. (c) Depiction of a TR-FRET competition-based assay. When a fluorescently labelled acceptor probe is complexed with POI-2, which in turn is bound to a fluorescent donor probe, a FRET signal is observed as the two fluorophores are in close proximity. No FRET signal is observed when the PROTAC displaces the probe. (d) Dose–response curve produced by a TR-FRET competition-based assay. As the concentration of PROTAC alone (black dotted line) or PROTAC:POI-1 complex increases, more fluorescently labelled probe is displaced from POI-2, resulting in a decrease in signal intensity. A rightward shift between binary and ternary binding indicates a negatively cooperative complex (green), no shift indicates a non-cooperative complex (red), and a leftward shift indicates a positively cooperative complex (blue)

The energy transfer process is slightly different between the two assays: AlphaLISA involves the conversion of oxygen into a more excited singlet state caused by laser excitation of a donor bead. This short-lived oxygen species diffuses across to the acceptor bead, activating the fluorophore and causing a fluorescence signal (Fig. 4a) [47]. In the case of TR-FRET, a FRET signal is generated by energy transfer between two complementary fluorophores of different wavelengths after being brought into close proximity (Fig. 4c) [45].

A common use of these proximity-based assays is to assess the relative population and concentration range at which ternary complexes form. To simply monitor PROTAC-induced ternary complex, a PROTAC is usually titrated into a system containing the two protein of interest (POI): POI-1 and POI-2 and their respective reporter species. As the concentration of PROTAC increases, there is a higher population of ternary complexes resulting in a higher output signal until a maxima is reached. It was discovered that more cooperative PROTACs tend to form highly populated ternary species, hence a higher signal intensity spanning over a wider range of concentrations (Fig. 4b) [14].

Gadd et al. developed an AlphaLISA assay to compare the relative ternary complex cooperativities between MZ1, VBC and different BET bromodomains [14]. They demonstrated that more cooperative complexes give a more intense output signal over a wider range of concentrations. To label their proteins, they used Ni-coated acceptor beads and streptavidin-coated donor beads which would bind to His-tagged bromodomains (BD) and biotinylated VBC, respectively. As the PROTAC is titrated into a system containing the individual proteins and respective beads, the ternary complex begins to form. This brings the beads into close proximity and emits fluorescence. As more PROTAC is titrated into the assay, more ternary complexes are formed and a higher intensity signal is received, until the hook effect kicks in. Others have adopted similar approaches to compare other VHL-recruiting degraders, which target other bromodomains such as Brd7/9 [30], and SMARCA2/4 [41], or to analyse CRBN-recruiting BET PROTACs [48, 49].

TR-FRET assays have been widely used to study ternary complexes formed by monovalent molecular glues such as IMiDs with the E3 ligase CRBN and recruited *neo*-substrate proteins [8], and more recently small-molecule enhancers of the oncogenic transcriptional factor, β -Catenin and the SCF ^{β -TrCP} E3 ligase [50]. TR-FRET assays have also been used for both CRBN-recruiting [29, 51] and VHL-recruiting degraders [52]. These examples follow a similar set-up whereby one of the target proteins is biotinylated and binds to a terbium or europium-coupled streptavidin donor. The other protein is labelled with an acceptor fluorophore such as BODIPY-FL or Alexa488. The mono- or bivalent

compound is titrated into the system and with increasing concentration, more ternary complexes form which results in a higher signal intensity.

2.3 Competitive and Direct Binding Assays

Although proximity assays offer fast and high-throughput methods for screening ternary complex formation, the bell-shaped curves produced, due to their complexity and overlapping events, are difficult to deconvolute in order to obtain accurate information about binary and ternary affinities and cooperativity. However, these problems can be circumvented by developing competitive and direct binding assays.

Label-dependent binding assays such as fluorescence polarisation (FP), TR-FRET and AlphaLISA among others can be used to gain key binding parameters such as the binary and ternary K_d and so the total ΔG for complex formation between target proteins and PROTACs. Such assays can be separated into two classes: competitive and direct binding assays.

Competition-based assays involve the displacement of a reporter species, usually a labelled small molecule or peptide, from one of the proteins recruited by a PROTAC. In competitive FP assays, as the labelled reporter is displaced by the PROTAC, the signal increases as more reporter species is released into solution. The opposite read-out is true for TR-FRET-based assays as decay in signal is observed due to the reporter no longer being in close proximity/bound for sufficient energy transfer to the fluorophore-containing POI (Fig. 4c). Competitive FP or TR-FRET is commonly used as primary screening assays due to their relative high-throughput prior to more quantitative techniques such as ITC and SPR. Recently, FP assays have been used to determine the stability and cooperativity of ternary complexes formed by different generations of VHL-recruiting PROTACs targeting Brd7/9 [30], and SMARCA2/4 [41]. In these studies, researchers compared PROTAC-induced, peptide displacement of a fluorescently labelled HIF-1 α (the natural substrate of VHL) bound to VBC in the presence or absence of the target protein. Cooperativity can then be determined by taking the ratio between K_d values—a rightward shift in the displacement profile of binary to ternary binding indicates negative cooperativity, a leftward shift for positive cooperativity, while no change in the displacement profile indicates a noncooperative complex (Fig. 4d). As an orthogonal assay, Farnaby et al. also adopted a competitive TR-FRET-based assay to measure the displacement of a biotinylated SMARCA2 probe in the presence or absence of VBC [41]. A similar competitive displacement approach was adopted for CRBN-recruiting degraders which target Brd4 [51].

AlphaLISA and TR-FRET can provide a direct read-out in ternary proximity assays and also provide an attractive approach to measure both binary and ternary binding affinities under

competitive modes. Other approaches such as ITC and SPR offer complementary, robust and label-free techniques to directly measure binary and ternary binding affinities and also provide important thermodynamic and kinetic binding parameters [53].

2.4 Isothermal Titration Calorimetry—Thermodynamics

Isothermal titration calorimetry (ITC) assays have been developed to provide a direct, label-free measurement of the thermodynamics of PROTAC-induced ternary complex formation in solution [14]. Key parameters such as associative binding constant (K_a) (and so the dissociation constant, K_d), changes in Gibb's free energy (ΔG) and entropy (ΔS), and also the stoichiometry of binding (N) can all be obtained from a single ITC experiment.

Gadd et al. devised a strategy where they performed reverse titrations POI-1 in the syringe and the PROTAC in the cell, instead of the more common approach involving titrating the small molecule from the syringe into a solution of protein in the cell. This was done to circumvent potential competing equilibria due to the hook effect during the titration. They first titrated POI-1 (BET BDs) into the PROTAC (MZ1) which gave a binary binding affinity for the PROTAC to the target protein ($K_d^{\text{POI-1}}$). This was followed by a further titration of POI-2 (VBC) into the saturated POI-1: PROTAC complex, giving a ternary binding affinity ($K_d^{\text{T, POI-2}}$). Because POI-1 and POI-2 do not interact alone in the absence of the PROTAC, any excess of the unbound POI-1 present in the cell from the first titration will not interfere with the heat signal obtained while titrating POI-2 to form the ternary complex. A separate titration of POI-2 into PROTAC alone is required to get a reference binary binding affinity ($K_d^{\text{POI-2}}$) which can be used to calculate the cooperativity of the ternary complex ($\alpha = K_d^{\text{POI-2}} / K_d^{\text{T, POI-2}}$) [14].

This approach has allowed full thermodynamic characterisation of PROTAC-induced ternary complexes for other VHL-recruiting degraders, which target other bromodomains such as Brd7/9 [30], and SMARCA2/4 [41], as well as PROTACs which dimerise an E3 ligase such as the VHL homo-PROTACs [17]. Although ITC can provide full characterisation of PROTAC-induced ternary complexes, the assay has limited throughput and requires relatively large quantities of material compared to most other assays.

2.4.1 Introduction to Biophysical Characterisation of PROTAC-Induced Ternary Complex Formation by Isothermal Titration Calorimetry Methods

An example of an isothermal titration calorimetry (ITC) procedure to interrogate formation of a ternary complex between VHL-Elongin B-Elongin C complex (VBC), a PROTAC compound, e.g. MZ1 and a BET bromodomain chosen between Brd2-BD1, Brd3-BD1, Brd4-BD1, Brd2-BD2, Brd3-BD2 and Brd4-BD2, is provided, as demonstrated by Gadd et al. in 2017 [14].

Mechanistic and Structural Features of PROTAC Ternary Complexes

2.4.2	<i>Materials</i>	1. ITC Buffer: 20 mM Bis-Tris Propane, pH ~7.4, 150 mM NaCl, 1 mM TCEP.	505 506
		2. DMSO.	507
		3. POI-1: BET bromodomain (BET BD).	508
		4. POI-2: VBC.	509
		5. PROTAC: MZ1.	510 511
2.4.3	<i>Methods</i>	Strategy: the experimental strategy involves running reversed titrations, i.e. POI-1 in the syringe, and PROTAC in the sample cell, to measure binary complex formation. This circumvents issues caused with the hook effect in a ternary titration, whereby the POI-2 is titrated into the remaining solution from the first titration of POI-1 into PROTAC.	512 513 514 515 516 517 518
Protein	Dialysis	1. Prepare 2 L of ITC buffer by first adding 1.5 L of water to a beaker and then bis-tris propane (11.33 g), sodium chloride (17.53 g) and tris(2-carboxyethyl)phosphine hydrochloride (TCEP·HCl) (573 mg). Adjust the pH to 7.4, make the solution up to 2 L in a measuring cylinder with water, transfer to a 2 L beaker, and finally store at 4 °C.	519 520 521 522 523 524
		2. Take desired amount of protein (BET BD and VBC) to be used for the following day. Dialyse these proteins in ITC buffer by using low molecular weight (~3.5 kDa) cut-off dialysis tubing, suspended in the 2 L beaker, and stir at 4 °C overnight.	525 526 527 528
		3. Following dialysis, transfer each protein into separate Eppendorf tubes and measure their concentrations in molar by taking three $A_{280\text{nm}}$ measurements per sample, calculating the mean from the three read-outs and then dividing by the protein's extinction coefficient.	529 530 531 532 533
		4. Take a large amount of dialysis buffer, and transfer to a Falcon tube by filtering through a 0.22 μm syringe filter to use for protein and sample dilutions and for cleaning the sample cell and Hamilton syringes.	534 535 536 537 538
PROTAC	Preparation	1. Dissolve PROTAC (MZ1) in dimethyl sulfoxide (DMSO) to make a 10 mM stock.	539 540
		2. For binary titrations between PROTAC and BET BD and for PROTAC and VBC, dilute the 10 mM stock in dialysis buffer by taking 2 μL of the 10 mM stock and adding 998 μL of dialysis buffer to obtain a final PROTAC concentration of 20 μM in ITC buffer and 0.2% (v/v) DMSO.	541 542 543 544 545 546
Protein	Preparation	1. Make a 10% (v/v) DMSO stock in dialysis buffer—required for matching up final DMSO concentration at 0.2% (v/v) in samples without PROTACs.	547 548 549

2. Make a 0.2% (v/v) DMSO stock in dialysis buffer—required for control titrations of protein into buffer and buffer into PROTAC and for washing syringe and sample cells between titrations.
3. Make a solution of at least 60 μL of BET BD at a concentration which is tenfold greater than that of the PROTAC (assuming a 1:1 binding stoichiometry), e.g. 200 μM in 0.2% (v/v) DMSO in dialysis buffer. If protein is plentiful, make a 100 μL solution by mixing the correct amount of protein stock with the original dialysis buffer containing NO DMSO to a volume of 98 μL in order to achieve a final concentration of 200 μM . Finally, top up with 2 μL of the 10% (v/v) DMSO in dialysis buffer stock to a total volume of 100 μL .
4. In order to run three VBC titrations with the same protein sample on the same day, make up 200 μL of VBC at 168 μM in 0.2% (v/v) DMSO in dialysis buffer. Do this by adding 4 μL of 10% (v/v) DMSO in dialysis buffer stock and adding the correct amount of protein to dilute to 168 μM . Finally, top up to 200 μL with the original dialysis buffer containing NO DMSO. The final concentration of VBC should be 168 μM due to that being 10 \times of the concentration at which the PROTAC gets diluted to in the cell at the end of the previous binary titration.

Note: accurate matching of final DMSO concentration across both sample cell and syringe solutions is critical to ensure high quality of data, as any potential mismatch in DMSO concentration between the two will lead to large heat of dilution from DMSO that can interfere with and even obscure the heat of binding that is to be measured.

Titration Procedure

Titration Procedure
 Titrations are performed using an ITC200 microcalorimeter (GE Healthcare). The titrations are performed in reverse mode (i.e. the protein in the syringe and the ligand in the sample cell). The experiment consists of $19 \times 2 \mu\text{L}$ injections of protein solution at a rate of 0.5 $\mu\text{L}/\text{s}$ in 120 s time intervals. An initial 0.4 μL injection of protein is made and discarded during data analysis, as per the manufacturer instruction. The experiments are performed at 25 $^{\circ}\text{C}$ with a stirring speed of 600 rpm.

Notes: Ensure to wash the syringe between titrations, using the dialysis buffer stock with 0.2% (v/v) DMSO.

DO NOT remove the solution remaining in the sample cell after performing a binary titration of protein into PROTAC and prior to performing the ternary titration.

Wash the sample cell after all titration experiments, except when performing a binary titration that needs to be followed by a ternary titration (see above).

	Degas all samples briefly under vacuum before loading them	596
	into the sample cell or syringe. This procedure will help to minimise	597
	the formation of air bubbles during the titration, which can lead to	598
	poor data and so ruin the experiment.	599
		600
Control Titrations	1. Titrate the 0.2% (v/v) DMSO in dialysis buffer stock into	601
	20 µM of PROTAC in 0.2% (v/v) DMSO. Do a separate	602
	titration of 0.2% (v/v) DMSO in dialysis buffer stock into	603
	16.8 µM of PROTAC in 0.2% (v/v) DMSO.	604
	2. Titrate 200 µM of BET BD in 0.2% (v/v) DMSO into 0.2%	605
	DMSO dialysis buffer stock. Do a separate titration with	606
	168 µM VBC in 0.2% (v/v) DMSO into 0.2% (v/v) DMSO	607
	dialysis buffer stock.	608
	3. The data from these control titrations can be used for baseline	609
	subtraction in binary and ternary titrations.	610
		611
Binary BET BD and Ternary Titrations	1. Titrate 200 µM of BET BD into 20 µM of PROTAC. Both	612
	were made with 0.2% (v/v) DMSO and dialysis buffer.	613
	2. Wash and dry the syringe and remove the excess solution from	614
	the top of the sample cell (as if starting the titration for the first	615
	time), and keep to one side in case of issues with the differential	616
	power (DP) or air bubbles.	617
	3. Titrate 168 µM of VBC into the sample cell which now con-	618
	tains 16.8 µM of PROTAC + stoichiometric excess of BET BD,	619
	remaining from the previous titration, again all in 0.2% (v/v)	620
	DMSO and dialysis buffer. This sample cell concentration was	621
	calculated as follows.	622
	$C = (C_0 [V]_{\text{cell}}) / (V_{\text{cell}} + V_{\text{inj}})$	623
	C_0 = Initial [PROTAC] in the cell (20 µM).	624
	V_{cell} = Volume of the sample cell (200.12 µL).	625
	V_{inj} = Volume of titrant injected initially (38.4 µL).	626
	Note: The experiment is conducted in this way to ensure	627
	that >99% of PROTAC is bound to the BET BD prior to	628
	injecting VBC into the cell. This experimental set-up assumes	629
	that VBC does not interact with the excess BET BD. This	630
	assumption can be easily checked by performing a control	631
	titration between the two proteins in the absence of PROTAC	632
	and comparing the observed heat with that from the	633
	corresponding control titration.	634
		635
VBC Binary Titration	In order to calculate cooperativity (α), a separate binary titration of	636
	VBC into PROTAC must be performed.	637
	1. Titrate the 0.2% (v/v) DMSO in dialysis buffer stock into	638
	20 µM of PROTAC in 0.2% (v/v) DMSO.	639

2. Wash and dry the syringe and remove the excess solution from the top of the sample cell (as if starting the titration for the first time), and keep to one side in case of issues with the DP or air bubbles. 640-643
3. Titrate 168 μM of VBC into the diluted PROTAC solution, again all in 0.2% (v/v) DMSO and dialysis buffer. 644-646

Data Analysis

Data is usually fitted using a single-binding site model to obtain stoichiometry n , the association constant K_a (from which the dissociation constant K_d can be readily calculated) and the enthalpy of binding ΔH using MicroCal LLC ITC200 Origin software which is provided by the manufacturer. The entropy of binding ΔS is also given by the MicroCal LLC ITC200 Origin software or can be obtained from the binding thermodynamics equation $\Delta S = (\Delta H - \Delta G)/T$, once the free energy ΔG is calculated from the measured K_a using the equation $\Delta G = -RT \times \ln(K_a)$. 647-656

2.5 Surface Plasmon Resonance—Kinetics

PROTAC delivers a kinetic cycle of recognition, target ubiquitination and degradation. The kinetics of each individual step in the mechanism therefore are likely to play an important role in the overall efficiency of the process, much as they do in enzyme catalysis [54]. However, until recently, the kinetics of PROTAC-induced ternary complex association and dissociation had not come into focus. This changed with a first study characterising the kinetics of PROTAC ternary complexes using SPR [35]. 657-664

Similarly to ITC, SPR is a label-free technique which can provide key thermodynamic binding parameters, K_a and K_d , of both binary and ternary complex formation but at a much higher throughput and offering, yet another way of quantifying cooperativity. In addition, SPR offers a unique way of characterising ternary complexes kinetically, by deconvoluting the associative (k_{on}) and dissociative (k_{off}) rate constants of the ternary complex equilibrium (Fig. 5). In 2019, Roy et al. developed the first SPR-based assay to measure the kinetics of PROTAC-induced ternary complexes [35]. They chose to benchmark their assay using the well-characterised PROTAC MZ1, as well as other BET targeting PROTACs which had also been characterised by ITC [14, 28, 35]. They designed a VBC construct which harboured an AviTag sequence on ElonginB for site-specific biotinylation (called ‘biotin-VCB’), and expressed, purified and immobilised the resulting biotinylated protein onto a streptavidin-loaded SPR chip. They then measured kinetics of the binary interaction between the immobilised VBC and PROTAC alone or the ternary interaction between the immobilised VBC and the preincubated, PROTAC:BD complex. The experiments revealed that the ternary complexes formed between VBC and MZ1 and Brd2^{BD2} and Brd4^{BD2} had the slowest dissociative half-life (calculated by $t_{1/2} = \ln 2/k_{off}$) of 67 and 130 s, 665-686




Fig. 5 Schematic representation of an SPR-based assay for binary and ternary complex formation. POI-2 is immobilised onto the sensor chip. For binary experiments (top), varying concentrations of PROTAC are flowed over the POI-2 immobilised surface resulting in a low maximal response (R_{max}) due to the relatively small increase in surface density. For ternary experiments (bottom), varying concentrations of PROTAC:POI-1 complex with excess POI-1 are flowed over the surface resulting in a high R_{max} . Examples of binding profiles for a single injection of PROTAC and PROTAC:POI-1 are shown (top right and bottom right, respectively). The ternary binding profile (bottom right) shows a comparison between a ternary complex with a long dissociative half-life ($t_{1/2}$) (red) and a ternary complex with a short $t_{1/2}$ (green). Kinetic parameters: k_{on} (associative rate constant), k_{off} (dissociative rate constant) and SS (steady state) are labelled

respectively, and much slower than Brd3^{BD2} ($t_{1/2} = 6$ s). Conversely, the fastest dissociating ternary complexes were formed with the first bromodomains (BD1) of Brd2, Brd3 and Brd4 with $t_{1/2} < 1$ s. Interestingly, the dissociative half-lives of the ternary complexes of VBC:MZ1 with the BD2s were found to correlate with the initial rates of degradation of the different BET proteins, with the most stable and long-lived complexes driving faster rate of target degradation, as a result of a greater level of protein ubiquitination [35]. Overall, these studies are providing emerging evidence that the lifetime and overall stability of the PROTAC ternary complex directly influence the outcome of target protein degradation [41, 35].

More recently, Pillow et al. adopted a similar SPR strategy, where they compare the JQ1-based BET degraders, MZ1 and ARV-771 with their new picomolar potent degrader, GNE-897. The ternary complex between VHL, GNE-897 and Brd4^{BD1} was found to have a dissociative half-life of just over 1 h [36]. These findings again demonstrate the relationship between a long-lived ternary complex and the potency of the degrader molecule.

In vitro biophysical methods offer key mechanistic insights into the way by which we perceive PROTAC-induced ternary complex formation. The techniques described above allow researchers to

fully characterise the formation and dissociation of PROTAC-induced ternary complex both thermodynamically and kinetically. As these techniques use mostly purified, recombinant protein constructs rather than full-length proteins, they provide a first shell of interactions so serve as good a model for how these compounds are behaving within the cell. To understand the full picture of ternary complexes, ultimately similar biophysical techniques and approaches must be incorporated or adapted to work into a more native environment.

3 Cellular and Functional Characterisation of Targeted Protein Degradation Mediated Via Ternary Complex Formation

3.1 Cellular Target Engagement Assays

PROTACs efficacy stems from the productive simultaneous engagement of both target protein and E3 ligase within the ternary complex. Therefore, PROTACs require the procurement of selective ligands for both targets. Conventionally, ligand-target engagement is observed via in vitro biophysical techniques using recombinant proteins; however, these approaches do not replicate the complexity of the intracellular environment adequately. Compound exposure is crucial to cellular target engagement and is affected by permeability, export/efflux, compound sequestration and protein compartmentalisation [55]. Inadequate exposure leads to lower efficacy, typified by compounds with high-affinity in vitro but lower affinity in cellular assays, a phenomenon termed ‘cell drop-off’ [56]. [Swinney, 2004 #4] Cell-based target engagement assays are therefore vital in the development of de novo small-molecule probes and PROTACs in early drug discovery.

3.1.1 Binary Target Engagement

Chemical proteomics approaches have, in recent years, emerged as a powerful method for measuring target engagement in cells. These approaches use occupancy probes that enrich specific target proteins from cell lysate for quantitative mass spectrometry analysis. These probes contain a selectivity handle (against the POI) and a functional moiety for immobilisation or protein isolation, e.g. biotin. The selectivity handle consists of either the compound being assessed (affinity-based probes) or a reactive group that irreversibly binds to the target (activity-based probes). Target engagement is observed through competition against an unmodified compound. Affinity-based probes have previously demonstrated a novel engagement of Buprenorphine for HDAC6/HDAC10 [57]. Similarly, fluorophosphate activity-based probe has observed uncharacterised serine hydrolases activity of protein within breast cancer tissue [58]. The improved kinobead solid-supported probes enabled analysis of the interactomes of 243 kinase inhibitors [59].

Advantages of activity-/affinity-based probes include complete proteome analysis within a single experiment and their

applicability in primary and patient-derived cell lines. Proteomic approaches, however, require cell lysis which disrupts the binding equilibria of reversible affinity-based probes. Photo-affinity labelling circumvents this problem via induced UV-mediated photocrosslinking of a probe to a target protein. Dasatinib and JQ1 inhibitors engagement was investigated using a 2-aryl-5-carboxytetrazole (ACT) photo-affinity label approach [60].

The cellular thermal shift assay (CETSA) is an alternative approach that requires no protein or compound modification. CETSA works on the principle of thermodynamic stabilisation induced by compound binding. Molina et al. recognised that compound-mediated thermodynamic stabilisation could be observed in cells and under nonlytic conditions up to 65 °C [61]. The compound-mediated shift in protein aggregation is quantifiable by different methods such as immunoblotting, reporter-based techniques and mass spectrometry. Combining CETSA and chemoproteomics approaches for target engagement, Klaeger et al. assessed the target engagement and selectivity profile of clinical kinase drugs [62]. Limitations of CETSA include the need for affinity reagents, i.e. antibodies, limitations of affinity free approaches, and a bias against protein complexes has been observed. Nanoluciferase thermal shift assay (NaLTSA), which measures thermodynamic stability as a luminescent output, circumvents the need for antibodies and has been implemented to detect inhibitor activity against kinases, bromodomains and HDACs. NaLTSA is amenable for high-throughput experiments making it an appealing alternative to CETSA [63].

Live cell imaging utilising fluorescent occupancy probes are appealing approaches for protein targets intractable to proteomic or thermostability-based methods, e.g. membrane proteins. In this approach, the fluorescent probe acts competitively against a non-derivatised compound added in a dose-dependent manner, as seen with CA200645 fluorescent probe being used to compete against compounds for binding with A3 and A1 receptors [64]. A limitation of fluorescent probes is that they must not be cross-selective as success is dependent on the proximal association of the fluorophore to the correct protein.

A similar approach termed fluorescence anisotropy (FA) or polarisation (FP) can observe compound engagement in live cells. Fluorescent polarisation has been shown at a single-cell resolution for observing ibrutinib and olaparib engagement in cells. The benefit of this approach is the increased spatial resolution, i.e. single-cell microscopy enabled observation of engagement heterogeneity among individual cells [65].

Despite requiring target and compound modification, Foerster resonance energy transfer (FRET) offers a direct, real-time, high-throughput screening approach for observing target engagement in

living cells. A limitation of FRET technologies is that the background fluorescence produces a poor signal-to-noise ratio. Time-resolved FRET (TR-FRET) improves the signal-to-noise ratio by using lanthanides which have an extended fluorescent half-life; however, TR-FRET is considered intractable for intracellular proteins without cell lysis.

An orthogonal approach that is tractable for intracellular proteins in live cells is bioluminescent resonance energy transfer (BRET). BRET uses a bioluminescent protein, such as the luciferase from *Renilla reniformis*, which does not require light excitation and benefits from a low background fluorescence [66]. Unlike TR-FRET, BRET has demonstrated engagement and residence time of HDAC inhibitors; SAHA, FK228 and TDP-A against target HDACs [67].

PROTAC degraders in their own right are emerging as potential chemical tools for target engagement studies. The idea is to derivatise small molecules with suspected target binding affinity into a bifunctional PROTAC molecule in the hope to identify one or more proteins being degraded, e.g. by proteomics, as a read-out for target engagement. This approach was applied to the compound CCT251236 to validate its engagement with the target protein pirin, which was confirmed via converting CCT251236 into a PROTAC and then observing degradation of pirin upon treatment of cells [68].

3.1.2 Target Engagement of the Ternary Complex

The PROTACs ternary complex is the key species in the PROTAC mechanism of action; therefore, understanding the formation efficiency and kinetics of ternary complexes within a cellular context is valuable in guiding structure–activity relationship (SAR) development of PROTAC compounds. Importantly, due to the potential transient and dynamic nature of the ternary complex, direct observation in cells can lead to false negatives results.

Whitworth et al. developed an optimised AlphaLISA assay for observing the ternary complex within cell lysates. PROTAC MZI-mediated ternary complex formation was probed using ectopically expressed FLAG-tag-conjugated BRD4-BD2 and biotinylated E3 ligase that could complex with a FLAG-tag-coated bead acceptor and streptavidin-coated bead donor. AlphaLISA signal was measured from the close proximity of FLAG-tagged acceptor beads to streptavidin donor beads. This research accomplished the first use of the AlphaLISA assay for observing ternary complex formation using full-length proteins natively expressed within cells [69]. As this is an endpoint assay, this system benefits for a detection mechanism not precluded by the degradation of the target protein; however, real-time observation of the ternary complex cannot be observed using this approach, and it is not generally suited for high-throughput screening applications.




Fig. 6 PROTAC based applications of the NanoBRET experimental platform. (a) Application of NanoBRET to determine the extent of PROTAC-mediated ternary complex formation. Fluorescence signal arise when a luminophore-tagged POI and a HaloTag-fused E3 ligase are brought into proximity. (b) Application of NanoBRET to determine the extent of PROTAC-induced target ubiquitination. Fluorescence signal arise when a luminophore-tagged POI is covalently modified with an ectopically expressed ubiquitin–HaloTag conjugate. PROTAC compound composed of POI ligand (green circle), E3 ligase (orange triangle) connected by a linker (black), POI (green), E3 (orange), NanoBIT/luciferase (blue), NanoBRET 618 Ligand (red), HaloTag–Ubiquitin (yellow and orange, respectively)

Another approach by Riching et al. uses the previously discussed BRET technology to determine ternary complex formation in living cells [70]. The approach termed NanoBRET utilises a NanoBiT luciferase-tagged protein donor and a HaloTag-conjugated protein labelled with the 618 ligand—a fluorophore-containing chloroalkane handle for use in the HaloTag technology—as the fluorescent acceptor (Fig. 6a). HiBiT, an 11-amino acid peptide tag, was conjugated to the BET proteins BRD2, BRD3 and BRD4. HiBiT complexed with the ectopically expressed LgBiT in a furimazine substrate environment produces luminescence. Cells containing HiBiT-conjugated BET proteins ectopically expressing HaloTag-conjugated VHL or CRBN, LgBiT, furimazine substrate, and 618 Ligand treated with either MZ1 or dBET1 PROTACs were monitored to observe ternary complex formation. The ratiometric nature of this approach makes it suitable for observation of the ternary complex as it is limitedly impacted by protein turnover; however, the addition of a proteasomal inhibitor can increase NanoBRET signal. One limitation of the NanoBRET system is that it has a weaker signal-to-noise ratio compared to non-FRET-based assays.

Phase-shift live cell imaging approaches have been used to observed ternary complex formation of PROTACs targeting BET proteins. SPPIER (separation of phase-based protein interaction reporter) by Chung et al. detected dBET1-, ARV-825 and

ARV-771-mediated ternary complex formation of BRD4 BDI with their respective E3 ligases [71]. SPPIER functions by the use of EGFP-HOTags conjugated to the interacting partners and upon initiation of a ternary complex induce the formation of a multi-domain complex transforming a diffuse EGFP signal into condensed detectable EGFP fluorescent puncta. A limitation of this approach is its low spatial resolution; however, its high brightness, distinct phase change and real-time applicability suggest this approach is amenable to high-throughput screening.

FLOUPPI (fluorescent-based technology detecting protein-protein interaction) approach also utilises phase-shift fluorescent imaging [72]. It involves the co-expression of an Azami-Green (AG)-fused protein and another assembly helper (Ash)-tagged proteins in cells. AG-derived fluorescence is diffuse in the absence of ternary complexing; however, once the engagement is initiated, AG-derived fluorescence produces fluorescent foci through complexing of the two proteins through Ash tags. dBET1 and ARV-825 induced the formation of GFP foci as a result of CRBN: BRD4: PROTAC ternary complex formation. FLOUPPI has a higher spatial resolution compared to SPPIER, enabling FLOUPPI to determine the intracellular localisation of PROTAC-mediated ternary complex formation. A possible limitation of this approach, however, is that nonspecific foci formation can occur as a result of target protein self-oligomerisation, thereby limiting the scope of this approach.

3.2 Cellular Target Ubiquitination and Degradation Assays

Ternary complex formation is a necessary step in the PROTAC mechanism of action, but may not be sufficient for downstream catalysis. Functional PROTACs must be able to induce ubiquitination of their protein targets before degradation can proceed. A PROTACs ability to induce productive ubiquitination is dependent on other factors, such as the relative configuration and stability of the ternary complex produced by a PROTAC, E3 ligase, and the target protein [35, 73]. Therefore, assays that can observe protein ubiquitination & degradation in a cell-based environment are instrumental for developing functional PROTACs.

3.2.1 Assessing Target Ubiquitination in Cells

Conventional methods for determining ubiquitination in PROTAC activity studies involves affinity tag pull-downs, or co-immunoprecipitation of PROTAC-treated cells with a western blot or mass spectrometry-based read-out. The abundance of different types of highly specific ubiquitin antibodies makes this approach amenable to most PROTAC activity studies.

Another aspect of ubiquitination is linkage type, with different linkages and chain lengths/topologies resulting in different cellular responses. Linear K48- and K63-linked ubiquitin strands are commonly studied in PROTAC activity studies since they facilitate recognition by the proteasome, for example, as presented by Chu

et al., demonstrating K48-specific polyubiquitination of Tau using a novel degrader TH006 [74]. Other linkage types are also probed since this can reveal information regarding E3 ligase activity and PROTAC efficacy. As seen when DT2216-mediated degradation of BCL-XL induced Lys 87 ubiquitination [75].

A complementary approach for determining linkage type is to use ectopically overexpressed lysine-substituted ubiquitin mutants. These ubiquitin mutants are deficient in the necessary lysine required for a single linkage type, by probing with different mutants it possible to determine linkage type of an enriched ubiquitinated protein. Ottis et al. demonstrated different ubiquitination linkage types produced by stably expressed E3 ligases–HaloTag conjugates. They concluded that different E3 ligases facilitate different linkage types, as an example, hijacking β -TrCP-induced formation of K48 linkages, while parkin led to K27 and K6 linkages [76].

Riching et al. have also developed two BRET-based assay for determining ubiquitination kinetics using the same HiBiT-BET conjugate donors discussed previously but paired with ectopically overexpressed HaloTag–Ubiquitin conjugate acceptor (Fig. 6b) [70]. In the presence of ligand 618 and ectopically expressed LgBIT, Riching et al. demonstrated rapid and more extensive ubiquitination of BRD2 and BRD4 in the presence of MZ1 PROTAC, relative to BRD3. The orthogonal approach, the NanoBRET™ immunoblot assay, utilises a polyclonal ubiquitin primary antibody and Alexa594-conjugated secondary antibody as an acceptor. Their results showed that both approaches show identical trends to those observed in the HaloTag–Ubiquitin kinetic experiments.

3.2.2 Assessing Protein Degradation in Cells

The last step of the PROTAC mechanism of action is protein degradation, and since functional PROTACs must be able to induce degradation, it is, therefore, imperative to have robust assays in hand to be able to observe degradation dynamics within a cellular context.

Given that the ternary complex has a bell-shaped isotherm, it is important to recognise that false negatives can arise from cellular degradation studies where PROTAC concentration exceeds maximal ternary complex formation, resulting in the ‘Hook effect’, so dose-dependent experiments are best performed in PROTAC activity studies (Fig. 7).

An important factor in degradation studies is the use of appropriate controls. An important control is the use of inactive PROTAC analogues that, for example, lack binding to the target or E3 ligase, as means to validate PROTAC mechanism of degradation. These are important controls because they control for ternary complex formation, and other artefacts, for example compound




Fig. 7 Hook effect observed in PROTAC-induced protein degradation and ternary complex formation. Representative western blot showing POI protein levels across a serial dilution of PROTAC concentration. The observed degradation effect correlates to the extent of PROTAC-mediated ternary complex formation as represented by the bell-shape curve shown above. PROTAC compound: POI ligand (orange triangle), E3 ligand (green square), connected by a linker; POI (orange), E3 (green)

binding, may destabilise the protein target in a PROTAC independent mechanism. An example of this latter mechanism is the study by Kerres et al., where binding to the BCL6 BTB domain was found to induce BCL6 degradation in a proteasomal-dependent fashion yet via an unknown mechanism [77].

Another parameter that can impact on the observed degradation is the target protein resynthesis rate. Commonly, washout experiments are performed, so that a degraded protein can be observed returning to a native protein level upon removal of the PROTAC compound from the cell medium. To this regards, proteins with a long half-life and so slow resynthesis rate would be expected to recover much slower than proteins with short half-life and fast resynthesis rate. However, even for the same target protein, it can be observed that recovery times can vary with different PROTAC compounds, presumably as the result of different cellular uptake and different ternary complex stabilities for the different

968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983

PROTACs [70]. Interestingly, some proteins have an accelerating 984
resynthesis rate as a result of transcriptional upregulation following 985
their cellular depletion. Recent proteomic approaches have enabled 986
precise quantitation of mature proteins separately from nascent 987
proteins, as well as monitoring the proteomic environment upon 988
degrader treatment over time. Savitski et al. using this approach 989
indicated that PROTAC degrader-mediated reduction in BRD2, 990
BRD3 and BRD4 protein levels does not accelerate their resynthe- 991
sis up to 24 h [78]. 992

Dose dependency, timing, and the extent of degradation 993
induced by PROTACs are the most commonly monitored assess- 994
ments of PROTAC efficacy in cells. These measurements are typi- 995
cally performed using immunoblotting. Zengerle et al. 996 AU9
demonstrated a standard dose-dependent cell-based immunoblot 997
assay of BET protein expression against treatment with different 998
concentrations of BET PROTAC degraders, which enabled us to 999
identify MZ1, the first BET PROTAC degrader that showed pref- 1000
erential degradation of Brd4 other the other BET proteins Brd2 1001
and Brd3 [33]. This approach is well established within the litera- 1002
ture, making it an attractive first approach for determining 1003
PROTAC-mediated degradation. There are limitations to using 1004
western botting, however, such as its semiquantitate nature, its 1005
limited dynamic range for low abundant proteins, the need of 1006
specific antibodies and its inability to track degradation in real 1007
time or in living cells. 1008

The modern capillary electrophoretic separation technique 1009
provided by ProteinSimple can improve upon immunoblotting 1010
quantitation and range [79]. Similarly, mass spectrometry can be 1011
implemented to improve quantitation in protein degradation stud- 1012
ies. However, these techniques are still unable to probe real-time 1013
degradation in living cells. 1014

Determining PROTAC degradation in living cells in real time 1015
has primarily been performed using ectopically expressed fluores- 1016
cent protein conjugates. Application of fluorescent conjugates has 1017
been demonstrated with MZ1-mediated degradation of 1018
GFP-tagged BRD4, and halo-PROTAC-induced degradation of 1019
Halo-GFP [33, 80]. While using florescent reporters enables the 1020
collection of real-time degradation data, ectopically expressed pro- 1021
tein conjugates utilise constitutive promoters, which can mask the 1022
real degradation kinetics. Gene tagging of a fluorescent reporter at 1023
endogenous level, e.g. using CRISPR-Cas9, can circumvent this 1024
issue; however, this requires significant time and effort and also 1025
risks altering the endogenous protein expression. An example of 1026
this from our own laboratory was described in the recent work by 1027
Tovell et al. where our optimised HaloPROTAC-E, a chloroalkane 1028
conjugate of high-affinity VHL binder VH298, induced reversible 1029
degradation of two HaloTag-tagged proteins, SGK3 and 1030
VPS34 [81]. 1031

A smaller tag can help reduce the time required in producing tagged protein and is less likely to abrogate protein function. Riching et al. used the NanoLuc split luciferase technology of HiBiT, and LgBiT discussed above to track dBET1- and MZ1-mediated degradation of BET proteins in real time in live cells [70]. The benefit of this approach is the small size of the integrated HiBiT tag, the extended dynamic range, absent the need for specific antibodies, its high resolution, and its real-time application makes it a tractable technology for PROTAC degradation studies.

3.2.3 Assessing Protein Degradation In Vivo

PROTACs are an exciting modality in drug discovery with great potential for therapeutic intervention. Despite this, in-vivo analysis of PROTAC efficacy is still in its infancy. The in-vivo analysis of PROTACs is of increasing importance as the field progresses towards clinical intervention—with two candidates currently in clinical trial: Arvinas's ARV-110 for prostate cancer and ARV-471 for breast cancer. Due to PROTACs typical lack of conformity with Lipinski's rule of five, it is crucial to determine PROTAC bioavailability and therefore in-vivo distribution parameters. The first in-vivo analysis of PROTAC efficacy was performed in 2015 in mice by two independent groups, where one explored the protein expression of ϵ RR α after treatment of 100 mg/kg ϵ RR α PROTAC in mouse heart and kidney cell and the other group determined tumour volume reduction in explanted MV4:11 cell in a mouse hind limb in response to DBET1 targeting of BET proteins [13, 82]. These initial in-vivo experiments established PROTAC efficacy via its impact on explanted tumour growth and determining endogenous mouse proteins levels using immunoblotting or proteomics approaches, however, were still limited to intraperitoneal or intravenous routes of administration. More recently, Sun et al. demonstrated both intraperitoneal and oral administration of FKBP12 degrader mediated rapid, and reversible FKBP12 degradation in mice and highlighted the clinical potential of oral administration of PROTACs [83]. This is now established as several orally bioavailable PROTACs have entered the clinic [84].

One recent development has been the utilisation of luciferase tagging to determine PROTAC efficacy in vivo using noninvasive bioluminescent imaging. Bioluminescent imaging is a powerful noninvasive optical imaging technique that works well in whole-murine models due to their naturally low intrinsic bioluminescence and that luminescence is penetrant up to several centimetres. An example of this approach enabled observation of real-time degradation of an FKBP12-conjugated luciferase in MV4;11 cells explanted into mice by novel VHL degrader compounds [85].

4 Concluding Remarks

1078

The catalytic, substoichiometric mode of action of PROTAC is underpinned by the ternary complexes they form with the target protein that is intended to be ubiquitinated and degraded and the recruited E3 ubiquitin ligase. Consequently, the ternary complex is a key intermediate species required for PROTAC mode of action. Despite this, the prevailing approach in the field has been to measuring directly and almost exclusively the final outcome, i.e. protein degradation, often coupled with measurement of binary inhibition/binding at the respective target and E3 ligase. However, recent studies have highlighted that ternary complex stability, cooperativity, kinetics and potentially geometry are emerging and important features that drive potency and efficiency of PROTAC-induced target degradation. As a result, much attention is now being devoted to approaches to studying the thermodynamics, kinetics and structural features of ternary complex formation equilibria and how these influence cellular activities. Here, we cover the key principles and methods being used to understand and study PROTAC ternary complexes and some of the key studies that have led to their current development. We advocate that these approaches and methods should instead be much more mainstream and be part of screening cascades to help guide and drive PROTAC design and characterisation campaigns. We anticipate that studies of ternary complexes and PROTAC mode of action will provide a fertile and exciting area of focus for important advances and method development in future.

1103

Acknowledgements and Funding

1104

We would like to thank many members of the Ciulli group for helpful discussions. We apologise to the authors of many studies in the field which could not be mentioned due to space restriction. The Ciulli laboratory's work on PROTACs has received funding from the European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007-2013) as a Starting Grant to A.C. (grant agreement No. ERC-2012-StG-311460 DrugE3CRLs). R.C. is funded by a PhD studentship from the UK Biotechnology and Biological Sciences Research Council (BBSRC) under the EastBio doctoral training programme (BB/M010996/1). A.B. is funded by a PhD studentship from the Medical Research Scotland (MRS) (1170-2017). C.C. is funded by a PhD studentship from the UK Medical Research Council (MRC) under the doctoral training programme in Quantitative and Interdisciplinary approaches to biomedical science (QI Biomed) (MR/N0123735/1). The Ciulli laboratory receives or has received

1120

sponsored research support from Boehringer Ingelheim, Eisai, Nurix, Ono Pharmaceuticals and Amphista Therapeutics. *Conflict of interest statement:* A.C. is the scientific founder, shareholder, nonexecutive director and consultant of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The remaining author reports no competing interests.

1129 References

- 1131 1. Hill AV (1910) The possible effects of the
1132 aggregation of the molecules of haemoglobin
1133 on its dissociation curves. *J Physiol Lond*
1134 40:4–7
- 1135 2. Labrijn AF, Janmaat ML, Reichert JM, Parren
1136 P (2019) Bispecific antibodies: a mechanistic
1137 review of the pipeline. *Nat Rev Drug Discov*
1138 18(8):585–608. [https://doi.org/10.1038/
1139 s41573-019-0028-1](https://doi.org/10.1038/s41573-019-0028-1)
- 1140 3. Profit AA, Lee TR, Lawrence DS (1999) Biva-
1141 lent inhibitors of protein tyrosine kinases. *J Am*
1142 *Chem Soc* 121(2):280–283. [https://doi.org/
1143 10.1021/ja983515n](https://doi.org/10.1021/ja983515n)
- 1144 4. Tanaka M, Roberts JM, Seo HS, Souza A,
1145 Paulk J, Scott TG, DeAngelo SL,
1146 Dhe-Paganon S, Bradner JE (2016) Design
1147 and characterization of bivalent BET inhibi-
1148 tors. *Nat Chem Biol* 12(12):1089–1096.
1149 <https://doi.org/10.1038/Nchembio.2209>
- 1150 5. Waring MJ, Chen HW, Rabow AA, Walker G,
1151 Bobby R, Boiko S, Bradbury RH, Callis R,
1152 Clark E, Dale I, Daniels DL, Dulak A,
1153 Flavell L, Holdgate G, Jowitt TA, Kikhney A,
1154 McAlister M, Mendez J, Ogg D, Patel J,
1155 Petteruti P, Robb GR, Robers MB, Saif S,
1156 Stratton N, Svergun DI, Wang WX,
1157 Whittaker D, Wilson DM, Yao Y (2016) Potent
1158 and selective bivalent inhibitors of BET bro-
1159 mododomains. *Nat Chem Biol* 12
1160 (12):1097–1104. [https://doi.org/10.1038/
1161 Nchembio.2210](https://doi.org/10.1038/Nchembio.2210)
- 1162 6. Che Y, Gilbert AM, Shanmugasundaram V,
1163 Noe MC (2018) Inducing protein-protein
1164 interactions with molecular glues. *Bioorg*
1165 *Med Chem Lett* 28(15):2585–2592. [https://
1166 doi.org/10.1016/j.bmcl.2018.04.046](https://doi.org/10.1016/j.bmcl.2018.04.046)
- 1167 7. Sun X, Gao H, Yang Y, He M, Wu Y, Song Y,
1168 Tong Y, Rao Y (2019) PROTACs: great oppor-
1169 tunities for academia and industry. *Signal*
1170 *Transduct Target Ther* 4:64. [https://doi.org/
1171 10.1038/s41392-019-0101-6](https://doi.org/10.1038/s41392-019-0101-6)
- 1172 8. Petzold G, Fischer ES, Thomä NH (2016)
1173 Structural basis of lenalidomide-induced
1174 CK1 α degradation by the CRL4CRBN
ubiquitin ligase. *Nature* 532(7597):127–130.
<https://doi.org/10.1038/nature16979>
9. Douglass EF Jr, Miller CJ, Sparer G,
Shapiro H, Spiegel DA (2013) A compre-
hensive mathematical model for three-body bind-
ing equilibria. *J Am Chem Soc* 135
(16):6092–6099. [https://doi.org/10.1021/
ja311795d](https://doi.org/10.1021/ja311795d)
10. Mack ET, Perez-Castillejos R, Suo Z, White-
sides GM (2008) Exact analysis of ligand-
induced dimerization of monomeric receptors.
Anal Chem 80(14):5550–5555. [https://doi.
org/10.1021/ac800578w](https://doi.org/10.1021/ac800578w)
11. Buxton BH (1905) Bacteriolytic power of
immune serum and the theory of complement
diversion. *J Med Res* 13(5):431–459
12. Mulgrew K, Kinneer K, Yao XT, Ward BK,
Damschroder MM, Walsh B, Mao SY, Gao C,
Kiener PA, Coats S, Kinch MS, Tice DA (2006)
Direct targeting of alphavbeta3 integrin on
tumor cells with a monoclonal antibody, Abe-
grin. *Mol Cancer Ther* 5(12):3122–3129.
[https://doi.org/10.1158/1535-7163.MCT-
06-0356](https://doi.org/10.1158/1535-7163.MCT-06-0356)
13. Bondeson DP, Mares A, Smith IE, Ko E,
Campos S, Miah AH, Mulholland KE,
Routly N, Buckley DL, Gustafson JL, Zinn N,
Grandi P, Shimamura S, Bergamini G, Faelth-
Savitski M, Bantscheff M, Cox C, Gordon DA,
Willard RR, Flanagan JJ, Casillas LN, Votta BJ,
den Besten W, Famm K, Kruidenier L, Carter
PS, Harling JD, Churcher I, Crews CM (2015)
Catalytic in vivo protein knockdown by small-
molecule PROTACs. *Nat Chem Biol* 11
(8):611–617. [https://doi.org/10.1038/
nchembio.1858](https://doi.org/10.1038/nchembio.1858)
14. Gadd MS, Testa A, Lucas X, Chan KH,
Chen W, Lamont DJ, Zengerle M, Ciulli A
(2017) Structural basis of PROTAC coopera-
tive recognition for selective protein degrada-
tion. *Nat Chem Biol* 13(5):514–521. [https://
doi.org/10.1038/nchembio.2329](https://doi.org/10.1038/nchembio.2329)
15. Bondeson DP, Smith BE, Burslem GM,
Buhimschi AD, Hines J, Jaime-Figueroa S,

- 1219 Wang J, Hamman BD, Ishchenko A, Crews
1220 CM (2018) Lessons in PROTAC design from
1221 selective degradation with a promiscuous war-
1222 head. *Cell Chem Biol* 25(1):78–87. e75.
1223 [https://doi.org/10.1016/j.chembiol.2017.](https://doi.org/10.1016/j.chembiol.2017.09.010)
1224 [09.010](https://doi.org/10.1016/j.chembiol.2017.09.010)
- 1225 16. Roy RD, Rosenmund C, Stefan MI (2017)
1226 Cooperative binding mitigates the high-dose
1227 hook effect. *BMC Syst Biol* 11(1):74.
1228 [https://doi.org/10.1186/s12918-017-0447-](https://doi.org/10.1186/s12918-017-0447-8)
1229 [8](https://doi.org/10.1186/s12918-017-0447-8)
- 1230 17. Maniaci C, Hughes SJ, Testa A, Chen WZ,
1231 Lamont DJ, Rocha S, Alessi DR, Romeo R,
1232 Ciulli A (2017) Homo-PROTACs: bivalent
1233 small-molecule dimerizers of the VHL E3 ubi-
1234 quitin ligase to induce self-degradation. *Nat*
1235 *Commun* 8(1):830. [https://doi.org/10.](https://doi.org/10.1038/s41467-017-00954-1)
1236 [1038/s41467-017-00954-1](https://doi.org/10.1038/s41467-017-00954-1)
- 1237 18. Steinebach C, Lindner S, Udeshi ND, Mani
1238 DC, Kehm H, Kopff S, Carr SA,
1239 Gutschow M, Kronke J (2018) Homo-
1240 PROTACs for the chemical knockdown of
1241 Cereblon. *ACS Chem Biol* 13(9):2771–2782.
1242 [https://doi.org/10.1021/acscchembio.](https://doi.org/10.1021/acscchembio.8b00693)
1243 [8b00693](https://doi.org/10.1021/acscchembio.8b00693)
- 1244 19. Saline M, Rodstrom KEJ, Fischer G, Orekhov
1245 VY, Karlsson BG, Lindkvist-Petersson K
1246 (2010) The structure of superantigen com-
1247 plexed with TCR and MHC reveals novel
1248 insights into superantigenic T cell activation.
1249 *Nat Commun* 1:119. [https://doi.org/10.](https://doi.org/10.1038/ncomms1117)
1250 [1038/ncomms1117](https://doi.org/10.1038/ncomms1117)
- 1251 20. Andersen PS, Schuck P, Sundberg EJ,
1252 Geisler C, Karjalainen K, Mariuzza RA (2002)
1253 Quantifying the energetics of cooperativity in a
1254 ternary protein complex. *Biochemistry* 41
1255 (16):5177–5184. [https://doi.org/10.1021/](https://doi.org/10.1021/bi0200209)
1256 [bi0200209](https://doi.org/10.1021/bi0200209)
- 1257 21. Choi JW, Chen J, Schreiber SL, Clardy J
1258 (1996) Structure of the FKBP12-rapamycin
1259 complex interacting with the binding domain
1260 of human FRAP. *Science* 273(5272):239–242.
1261 [https://doi.org/10.1126/science.273.5272.](https://doi.org/10.1126/science.273.5272.239)
1262 [239](https://doi.org/10.1126/science.273.5272.239)
- 1263 22. Kepinski S, Leyser O (2005) The Arabidopsis
1264 F-box protein TIR1 is an auxin receptor.
1265 *Nature* 435(7041):446–451. [https://doi.](https://doi.org/10.1038/nature03542)
1266 [org/10.1038/nature03542](https://doi.org/10.1038/nature03542)
- 1267 23. Banaszynski LA, Liu CW, Wandless TJ (2005)
1268 Characterization of the FKBP center dot rapa-
1269 mycin center dot FRB ternary complex. *J Am*
1270 *Chem Soc* 127(13):4715–4721. [https://doi.](https://doi.org/10.1021/ja043277y)
1271 [org/10.1021/ja043277y](https://doi.org/10.1021/ja043277y)
- 1272 24. Chamberlain PP, Cathers BE (2019) Cereblon
1273 modulators: low molecular weight inducers of
1274 protein degradation. *Drug Discov Today Technol*
1275 31:29–34. [https://doi.org/10.1016/j.](https://doi.org/10.1016/j.ddtec.2019.02.004)
1276 [ddtec.2019.02.004](https://doi.org/10.1016/j.ddtec.2019.02.004)
25. Han T, Goralski M, Gaskill N, Capota E, Kim J,
Ting TC, Xie Y, Williams NS, Nijhawan D
(2017) Anticancer sulfonamides target splicing
by inducing RBM39 degradation via recruit-
ment to DCAF15. *Science* 356(6336):
eaal3755. [https://doi.org/10.1126/science.](https://doi.org/10.1126/science.aal3755)
[aal3755](https://doi.org/10.1126/science.aal3755)
26. Uehara T, Minoshima Y, Sagane K, Sugi NH,
Mitsuhashi KO, Yamamoto N, Kamiyama H,
Takahashi K, Kotake Y, Uesugi M, Yokoi A,
Inoue A, Yoshida T, Mabuchi M, Tanaka A,
Owa T (2017) Selective degradation of splicing
factor CAPERalpha by anticancer sulfona-
mides. *Nat Chem Biol* 13(6):675–680.
<https://doi.org/10.1038/nchembio.2363>
27. Bussiere DE, Xie LL, Srinivas H, Shu W,
Burke A, Be C, Zhao JP, Godbole A, King D,
Karki RG, Hornak V, Xu FM, Cobb J, Carte N,
Frank AO, Frommlet A, Graff P, Knapp M,
Fazal A, Okram B, Jiang SC, Michellys PY,
Beckwith R, Voshol H, Wiesmann C, Solomon
JM, Paulk J (2020) Structural basis of
indisulam-mediated RBM39 recruitment to
DCAF15 E3 ligase complex. *Nat Chem Biol*
16(1):15–23. [https://doi.org/10.1038/](https://doi.org/10.1038/s41589-019-0411-6)
[s41589-019-0411-6](https://doi.org/10.1038/s41589-019-0411-6)
28. Chan KH, Zengerle M, Testa A, Ciulli A
(2018) Impact of target warhead and linkage
vector on inducing protein degradation: com-
parison of Bromodomain and extra-terminal
(BET) degraders derived from Triazolodiaze-
pine (JQ1) and Tetrahydroquinoline
(I-BET726) BET inhibitor scaffolds. *J Med*
Chem 61(2):504–513. [https://doi.org/10.](https://doi.org/10.1021/acscimedchem.6b01912)
[1021/acscimedchem.6b01912](https://doi.org/10.1021/acscimedchem.6b01912)
29. Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K,
Smith J, Zhu H, Farley KA, Ding W,
Schiemer J, Feng X, Chang JS, Uccello DP,
Young JA, Garcia-Irrizary CN, Czabaniuk L,
Schuff B, Oliver R, Montgomery J, Hayward
MM, Coe J, Chen J, Niosi M, Luthra S, Shah
JC, El-Kattan A, Qiu X, West GM, Noe MC,
Shanmugasundaram V, Gilbert AM, Brown
MF, Calabrese MF (2018) Delineating the
role of cooperativity in the design of potent
PROTACs for BTK. *Proc Natl Acad Sci U S*
A 115(31):E7285–E7292. [https://doi.org/](https://doi.org/10.1073/pnas.1803662115)
[10.1073/pnas.1803662115](https://doi.org/10.1073/pnas.1803662115)
30. Zoppi V, Hughes SJ, Maniaci C, Testa A,
Gmaschitz T, Wieshofer C, Koegl M, Riching
KM, Daniels DL, Spallarossa A, Ciulli A (2019)
Iterative design and optimization of initially
inactive proteolysis targeting chimeras (PRO-
TACs) identify VZ185 as a potent, fast, and
selective von Hippel-Lindau (VHL) based
dual degrader probe of BRD9 and BRD7. *J*
Med Chem 62(2):699–726. [https://doi.org/](https://doi.org/10.1021/acscimedchem.8b01413)
[10.1021/acscimedchem.8b01413](https://doi.org/10.1021/acscimedchem.8b01413)

- 1335 31. Yang JL, Li YB, Aguilar A, Liu ZM, Yang CY, 1393
1336 Wang SM (2019) Simple structural modifica- 1394
1337 tions converting a Bona fide MDM2 PROTAC 1395
1338 degrader into a molecular glue molecule: a 1396
1339 cautionary tale in the design of PROTAC 1397
1340 degraders. *J Med Chem* 62(21):9471–9487. 1398
1341 [https://doi.org/10.1021/acs.jmedchem.](https://doi.org/10.1021/acs.jmedchem.9b00846) 1399
1342 [9b00846](https://doi.org/10.1021/acs.jmedchem.9b00846) 1400
- 1343 32. Ishoey M, Chorn S, Singh N, Jaeger MG, 1401
1344 Brand M, Paulk J, Bauer S, Erb MA, 1402
1345 Parapaties K, Muller AC, Bennett KL, Ecker 1403
1346 GF, Bradner JE, Winter GE (2018) Translation 1404
1347 termination factor GSPT1 is a phenotypically 1405
1348 relevant off-target of heterobifunctional Phtha- 1406
1349 limide degraders. *ACS Chem Biol* 13 1407
1350 (3):553–560. [https://doi.org/10.1021/](https://doi.org/10.1021/acschembio.7b00969) 1408
1351 [acschembio.7b00969](https://doi.org/10.1021/acschembio.7b00969) 1409
- 1352 33. Zengerle M, Chan KH, Ciulli A (2015) Selec- 1410
1353 tive small molecule induced degradation of the 1411
1354 BET Bromodomain protein BRD4. *ACS* 1412
1355 *Chem Biol* 10(8):1770–1777. [https://doi.](https://doi.org/10.1021/acschembio.5b00216) 1413
1356 [org/10.1021/acschembio.5b00216](https://doi.org/10.1021/acschembio.5b00216) 1414
- 1357 34. Baud MGJ, Lin-Shiao E, Cardote T, Tallant C, 1415
1358 Pschibul A, Chan KH, Zengerle M, Garcia JR, 1416
1359 Kwan TT, Ferguson FM, Ciulli A (2014) 1417
1360 Chemical biology. A bump-and-hole approach 1418
1361 to engineer controlled selectivity of BET bro- 1419
1362 modomain chemical probes. *Science* 346 1420
1363 (6209):638–641. [https://doi.org/10.1126/](https://doi.org/10.1126/science.1249830) 1421
1364 [science.1249830](https://doi.org/10.1126/science.1249830) 1422
- 1365 35. Roy MJ, Winkler S, Hughes SJ, Whitworth C, 1423
1366 Galant M, Farnaby W, Rumpel K, Ciulli A 1424
1367 (2019) SPR-measured dissociation kinetics of 1425
1368 PROTAC ternary complexes influence target 1426
1369 degradation rate. *ACS Chem Biol* 14 1427
1370 (3):361–368. [https://doi.org/10.1021/](https://doi.org/10.1021/acschembio.9b00092) 1428
1371 [acschembio.9b00092](https://doi.org/10.1021/acschembio.9b00092) 1429
- 1372 36. Pillow TH, Adhikari P, Blake RA, Chen J, Del 1430
1373 Rosario G, Deshmukh G, Figueroa I, Gas- 1431
1374 coigne KE, Kamath AV, Kaufman S, 1432
1375 Kleinheinz T, Kozak KR, Latifi B, Leipold 1433
1376 DD, Sing Li C, Li R, Mulvihill MM, 1434
1377 O'Donohue A, Rowntree RK, Sadowsky JD, 1435
1378 Wai J, Wang X, Wu C, Xu Z, Yao H, Yu SF, 1436
1379 Zhang D, Zang R, Zhang H, Zhou H, Zhu X, 1437
1380 Dragovich PS (2020) Antibody conjugation of 1438
1381 a chimeric BET degrader enables in vivo activ- 1439
1382 ity. *ChemMedChem* 15(1):17–25. [https://](https://doi.org/10.1002/cmdc.201900497) 1440
1383 doi.org/10.1002/cmdc.201900497 1441
- 1384 37. Testa A, Lucas X, Castro GV, Chan KH, Wright 1442
1385 JE, Runcie AC, Gadd MS, Harrison WTA, Ko 1443
1386 EJ, Fletcher D, Ciulli A (2018) 3-Fluoro-4- 1444
1387 hydroxyprolines: synthesis, conformational 1445
1388 analysis, and Stereoselective recognition by 1446
1389 the VHL E3 ubiquitin ligase for targeted pro- 1447
1390 tein degradation. *J Am Chem Soc* 140 1448
1391 (29):9299–9313. [https://doi.org/10.1021/](https://doi.org/10.1021/jacs.8b05807) 1449
1392 [jacs.8b05807](https://doi.org/10.1021/jacs.8b05807) 1450
38. Han X, Zhao L, Xiang W, Qin C, Miao B, Xu T, 1393
1394 Wang M, Yang CY, Chinnaswamy K, Stuckey J, 1395
1396 Wang S (2019) Discovery of highly potent and 1396
1397 efficient PROTAC degraders of androgen 1397
1398 receptor (AR) by employing weak binding 1398
1399 affinity VHL E3 ligase ligands. *J Med Chem* 1399
1400 62(24):11218–11231. [https://doi.org/10.](https://doi.org/10.1021/acs.jmedchem.9b01393) 1401
1402 [1021/acs.jmedchem.9b01393](https://doi.org/10.1021/acs.jmedchem.9b01393) 1402
39. Testa A, Hughes SJ, Lucas X, Wright JE, Ciulli 1401
1402 A (2020) Structure-based Design of a Macro- 1402
1403 cyclic PROTAC. *Angew Chem Int Edit* 59 1403
1404 (4):1727–1734. [https://doi.org/10.1002/](https://doi.org/10.1002/anie.201914396) 1404
1405 [anie.201914396](https://doi.org/10.1002/anie.201914396) 1405
40. Soumana DI, Yilmaz NK, Prachanronarong 1406
1407 KL, Aydin C, Ali A, Schiffer CA (2016) Struc- 1407
1408 tural and thermodynamic effects of macrocycli- 1408
1409 zation in HCV NS3/4A inhibitor MK-5172. 1409
1410 *ACS Chem Biol* 11(4):900–909. [https://doi.](https://doi.org/10.1021/acschembio.5b00647) 1410
1411 [org/10.1021/acschembio.5b00647](https://doi.org/10.1021/acschembio.5b00647) 1411
41. Farnaby W, Koegl M, Roy MJ, Whitworth C, 1412
1413 Diers E, Trainor N, Zollman D, Steurer S, 1413
1414 Karolyi-Oezguer J, Riedmueller C, 1414
1415 Gmaschitz T, Wachter J, Dank C, Galant M, 1415
1416 Sharps B, Rumpel K, Traxler E, Gerstberger T, 1416
1417 Schnitzer R, Petermann O, Greb P, 1417
1418 Weinstabl H, Bader G, Zoephel A, Weiss- 1418
1419 Puxbaum A, Ehrenhofer-Wolfer K, Wohrle S, 1419
1420 Boehmelt G, Rinnenthal J, Arnhof H, 1420
1421 Wiechens N, Wu MY, Owen-Hughes T, 1421
1422 Ettmayer P, Pearson M, McConnell DB, Ciulli 1422
1423 A (2019) BAF complex vulnerabilities in cancer 1423
1424 demonstrated via structure-based PROTAC 1424
1425 design. *Nat Chem Biol* 15(7):672–680. 1425
1426 [https://doi.org/10.1038/s41589-019-0294-](https://doi.org/10.1038/s41589-019-0294-6) 1426
1427 [6](https://doi.org/10.1038/s41589-019-0294-6) 1427
42. Vangamudi B, Paul TA, Shah PK, Kost- 1428
1429 Alimova M, Nottebaum L, Shi X, Zhan YA, 1429
1430 Leo E, Mahadeshwar HS, Protopopov A, 1430
1431 Futreal A, Tieu TN, Peoples M, Heffernan 1431
1432 TP, Marszalek JR, Toniatti C, Petrocchi A, 1432
1433 Verhelle D, Owen DR, Draetta G, Jones P, 1433
1434 Palmer WS, Sharma S, Andersen JN (2015) 1434
1435 The SMARCA2/4 ATPase domain surpasses 1435
1436 the Bromodomain as a drug target in 1436
1437 SWI/SNFMutant cancers: insights from 1437
1438 cDNA rescue and PFI-3 inhibitor studies. *Cancer* 1438
1439 *Res* 75(18):3865–3878. [https://doi.org/](https://doi.org/10.1158/0008-5472.Can-14-3798) 1439
1440 [10.1158/0008-5472.Can-14-3798](https://doi.org/10.1158/0008-5472.Can-14-3798) 1440
43. Albrecht B, Cote A, Crawford T, Duplessis M, 1441
1442 Good A, Leblanc Y, Magnuson S, 1442
1443 Naveschuk C, Romero F, Tang Y (2016) 1443
1444 Therapeutic pyridazine compounds and uses 1444
1445 thereof WIPO patent WO2016138114 1445
44. Soares P, Gadd MS, Frost J, Galdeano C, 1446
1447 Ellis L, Epemolu O, Rocha S, Read KD, Ciulli 1447
1448 A (2018) Group-based optimization of potent 1448
1449 and cell-active inhibitors of the von Hippel- 1449
1450 Lindau (VHL) E3 ubiquitin ligase: structure- 1450

- 1451 activity relationships leading to the chemical
1452 probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropa-
1453 necarboxamido)-3,3-dimethylbutanoyl)-4-
1454 hydroxy-N-(4-(4-methylthiazol-5-yl)benzyp-
1455 pyrrolidine-2-carboxamide) (VH298). *J Med*
1456 *Chem* 61(2):599–618. [https://doi.org/10.](https://doi.org/10.1021/acs.jmedchem.7b00675)
1457 [1021/acs.jmedchem.7b00675](https://doi.org/10.1021/acs.jmedchem.7b00675)
- 1458 45. Lebakken CS, Riddle SM, Singh U, Frazee WJ,
1459 Eliason HC, Gao Y, Reichling LJ, Marks BD,
1460 Vogel KW (2009) Development and applica-
1461 tions of a broad-coverage, TR-FRET-based
1462 kinase binding assay platform. *J Biomol Screen*
1463 14(8):924–935. [https://doi.org/10.1177/](https://doi.org/10.1177/1087057109339207)
1464 [1087057109339207](https://doi.org/10.1177/1087057109339207)
- 1465 46. Glickman JF, Wu X, Mercuri R, Illy C, Bowen
1466 BR, He Y, Sills M (2002) A comparison of
1467 ALPHAScreen, TR-FRET, and TRF as assay
1468 methods for FXR nuclear receptors. *J Biomol*
1469 *Screen* 7(1):3–10. [https://doi.org/10.1177/](https://doi.org/10.1177/108705710200700102)
1470 [108705710200700102](https://doi.org/10.1177/108705710200700102)
- 1471 47. Beaudet L, Rodriguez-Suarez R, Venne M-H,
1472 Caron M, Bédard J, Brechler V, Parent S, Bie-
1473 lefeld-Sévigny M (2008) AlphaLISA immu-
1474 noassays: the no-wash alternative to ELISAs
1475 for research and drug discovery. *Nat Methods*
1476 5(12):A10
- 1477 48. Winter GE, Mayer A, Buckley DL, Erb MA,
1478 Roderick JE, Vittori S, Reyes JM, di Iulio J,
1479 Souza A, Ott CJ, Roberts JM, Zeid R, Scott
1480 TG, Paulk J, Lachance K, Olson CM,
1481 Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher
1482 MA, Churchman LS, Bradner JE (2017) BET
1483 Bromodomain proteins function as master
1484 transcription elongation factors independent
1485 of CDK9 recruitment. *Mol Cell* 67(1):5–18.
1486 e19. [https://doi.org/10.1016/j.molcel.2017.](https://doi.org/10.1016/j.molcel.2017.06.004)
1487 [06.004](https://doi.org/10.1016/j.molcel.2017.06.004)
- 1488 49. Wurz RP, Dellamaggiore K, Dou H, Javier N,
1489 Lo M-C, McCarter JD, Mohl D, Sastri C, Lip-
1490 ford JR, Cee VJ (2018) A “click chemistry
1491 platform” for the rapid synthesis of bispecific
1492 molecules for inducing protein degradation. *J*
1493 *Med Chem* 61(2):453–461. [https://doi.org/](https://doi.org/10.1021/acs.jmedchem.6b01781)
1494 [10.1021/acs.jmedchem.6b01781](https://doi.org/10.1021/acs.jmedchem.6b01781)
- 1495 50. Simonetta KR, Taygerly J, Boyle K, Basham
1496 SE, Padovani C, Lou Y, Cummins TJ, Yung
1497 SL, von Soly SK, Kayser F, Kuriyan J,
1498 Rape M, Cardozo M, Gallop MA, Bence NF,
1499 Barsanti PA, Saha A (2019) Prospective discov-
1500 ery of small molecule enhancers of an E3 ligase-
1501 substrate interaction. *Nat Commun* 10
1502 (1):1402. [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-019-09358-9)
1503 [019-09358-9](https://doi.org/10.1038/s41467-019-09358-9)
- 1504 51. Nowak RP, DeAngelo SL, Buckley D, He Z,
1505 Donovan KA, An J, Safaei N, Jedrychowski
1506 MP, Ponthier CM, Ishoey M, Zhang T, Man-
1507 cias JD, Gray NS, Bradner JE, Fischer ES
1508 (2018) Plasticity in binding confers selectivity
in ligand-induced protein degradation. *Nat*
Chem Biol 14(7):706–714. [https://doi.org/](https://doi.org/10.1038/s41589-018-0055-y)
[10.1038/s41589-018-0055-y](https://doi.org/10.1038/s41589-018-0055-y)
52. Hsu JH-R, Rasmussen T, Robinson J, Pachl F,
Read J, Kawatkar S, O'Donovan DH, Bagal S,
Code E, Rawlins P, Argyrou A, Tomlinson R,
Gao N, Zhu X, Chiarparin E, Jacques K,
Shen M, Woods H, Bednarski E, Wilson DM,
Drew L, Castaldi MP, Fawell S, Bloecher A
(2020) EED-targeted PROTACs degrade
EED, EZH2, and SUZ12 in the PRC2 com-
plex. *Cell Chem Biol* 27(1):41–46.e17.
[https://doi.org/10.1016/j.chembiol.2019.](https://doi.org/10.1016/j.chembiol.2019.11.004)
[11.004](https://doi.org/10.1016/j.chembiol.2019.11.004)
53. Ciulli A (2013) Biophysical screening for the
discovery of small-molecule ligands. In: Wil-
liams MA, Daviter T (eds) Protein-ligand inter-
actions: methods and applications. Humana
Press, Totowa, NJ, pp 357–388. [https://doi.](https://doi.org/10.1007/978-1-62703-398-5_13)
[org/10.1007/978-1-62703-398-5_13](https://doi.org/10.1007/978-1-62703-398-5_13)
54. Fisher SL, Phillips AJ (2018) Targeted protein
degradation and the enzymology of degraders.
Curr Opin Chem Biol 44:47–55. [https://doi.](https://doi.org/10.1016/j.cbpa.2018.05.004)
[org/10.1016/j.cbpa.2018.05.004](https://doi.org/10.1016/j.cbpa.2018.05.004)
55. Hann MM, Simpson GL (2014) Intracellular
drug concentration and disposition—the miss-
ing link? *Methods* 68(2):283–285. [https://](https://doi.org/10.1016/j.ymeth.2014.05.009)
doi.org/10.1016/j.ymeth.2014.05.009
56. Swinney DC (2004) Biochemical mechanisms
of drug action: what does it take for success?
Nat Rev Drug Discov 3(9):801–808. [https://](https://doi.org/10.1038/nrd1500)
doi.org/10.1038/nrd1500
57. Bantscheff M, Hopf C, Savitski MM,
Dittmann A, Grandi P, Michon A-M,
Schlegl J, Abraham Y, Becher I, Bergamini G,
Boesche M, Delling M, Dümpelfeld B,
Eberhard D, Huthmacher C, Mathieson T,
Poeckel D, Reader V, Strunk K, Sweetman G,
Kruse U, Neubauer G, Ramsden NG, Drewes
G (2011) Chemoproteomics profiling of
HDAC inhibitors reveals selective targeting of
HDAC complexes. *Nat Biotechnol* 29
(3):255–265. [https://doi.org/10.1038/nbt.](https://doi.org/10.1038/nbt.1759)
[1759](https://doi.org/10.1038/nbt.1759)
58. Jessani N, Niessen S, Wei BQ, Nicolau M,
Humphrey M, Ji Y, Han W, Noh D-Y, Yates
JR, Jeffrey SS, Cravatt BF (2005) A stream-
lined platform for high-content functional pro-
teomics of primary human specimens. *Nat*
Methods 2(9):691–697. [https://doi.org/10.](https://doi.org/10.1038/nmeth778)
[1038/nmeth778](https://doi.org/10.1038/nmeth778)
59. Médard G, Pachl F, Ruprecht B, Klaeger S,
Heinzlmeir S, Helm D, Qiao H, Ku X,
Wilhelm M, Kuehne T, Wu Z, Dittmann A,
Hopf C, Kramer K, Kuster B (2015) Opti-
mized chemical proteomics assay for kinase
inhibitor profiling. *J Proteome Res* 14

- 1566 (3):1574–1586. [https://doi.org/10.1021/](https://doi.org/10.1021/pr5012608)
1567 [pr5012608](https://doi.org/10.1021/pr5012608)
- 1568 60. AS H, Marjanovic J, Lewandowski TM,
1569 Marin V, Patterson M, Miesbauer L, Ready D,
1570 Williams J, Vasudevan A, Lin Q (2016) 2-Aryl-
1571 5-carboxytetrazole as a new photoaffinity label
1572 for drug target identification. *J Am Chem Soc*
1573 138(44):14609–14615. [https://doi.org/10.](https://doi.org/10.1021/jacs.6b06645)
1574 [1021/jacs.6b06645](https://doi.org/10.1021/jacs.6b06645)
- 1575 61. Molina DM, Jafari R, Ignatushchenko M,
1576 Seki T, Larsson EA, Dan C, Sreekumar L,
1577 Cao Y, Nordlund P (2013) Monitoring drug
1578 target engagement in cells and tissues using the
1579 cellular thermal shift assay. *Science* 341
1580 (6141):84–87
- 1581 62. Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H,
1582 Vick B, Koenig PA, Reinecke M, Ruprecht B,
1583 Petzoldt S, Meng C, Zecha J, Reiter K,
1584 Qiao H, Helm D, Koch H, Schoof M,
1585 Canevari G, Casale E, Depaolini SR,
1586 Feuchtinger A, Wu Z, Schmidt T, Rueckert L,
1587 Becker W, Huenges J, Garz AK, Gohlke BO,
1588 Zolg DP, Kayser G, Voeder T, Preissner R,
1589 Hahne H, Tönisson N, Kramer K, Götze K,
1590 Bassermann F, Schlegl J, Ehrlich HC, Aiche S,
1591 Walch A, Greif PA, Schneider S, Felder ER,
1592 Ruland J, Médard G, Jeremias I,
1593 Spiekermann K, Kuster B (2017) The target
1594 landscape of clinical kinase drugs. *Science* 358
1595 (6367):eaan4368
- 1596 63. Dart ML, Machleidt T, Jost E, Schwinn MK,
1597 Robers MB, Shi C, Kirkland TA, Killoran MP,
1598 Wilkinson JM, Hartnett JR, Zimmerman K,
1599 Wood KV (2018) Homogeneous assay for tar-
1600 get engagement utilizing bioluminescent ther-
1601 mal shift. *ACS Med Chem Lett* 9(6):546–551
- 1602 64. Stoddart LA, Vernall AJ, Denman JL, Briddon
1603 SJ, Kellam B, Hill SJ (2012) Fragment screen-
1604 ing at adenosine-A3 receptors in living cells
1605 using a fluorescence-based binding assay.
1606 *Chem Biol* 19(9):1105–1115
- 1607 65. Dubach JM, Kim E, Yang K, Cuccarese M,
1608 Giedt RJ, Meimetis LG, Vinegoni C, Weissler
1609 R (2017) Quantitating drug-target
1610 engagement in single cells in vitro and in vivo.
1611 *Nat Chem Biol* 13(2):168–173
- 1612 66. Goyet E, Bouquier N, Ollendorff V, Perroy J
1613 (2016) Fast and high resolution single-cell
1614 BRET imaging. *Sci Rep* 6(1):28231
- 1615 67. Robers MB, Dart ML, Woodrooffe CC, Zim-
1616 prich CA, Kirkland TA, Machleidt T, Kupcho
1617 KR, Levin S, Hartnett JR, Zimmerman K,
1618 Niles AL, Ohana RF, Daniels DL, Slater M,
1619 Wood MG, Cong M, Cheng YQ, Wood KV
1620 (2015) Target engagement and drug residence
1621 time can be observed in living cells with BRET.
1622 *Nat Commun* 6:10091
68. Chessum NEA, Sharp SY, Caldwell JJ, Pasqua
1623 AE, Wilding B, Colombano G, Collins I,
1624 Ozer B, Richards M, Rowlands M, Stubbs M,
1625 Burke R, McAndrew PC, Clarke PA,
1626 Workman P, Cheeseman MD, Jones K (2018)
1627 Demonstrating in-cell target engagement
1628 using a pirin protein degradation probe
1629 (CCT367766). *J Med Chem* 61(3):918–933
1630
69. Whitworth C, Farnaby W, Koegl M,
1631 Schnitzer R, Steurer S, Ettmayer P, Ciulli A
1632 (2018) PO-449 optimisation of an AlphaLISA
1633 assay for the characterisation of PROTAC-
1634 induced ternary complexes within cell lysates.
1635 *ESMO Open* 3(Suppl 2):A198
1636
70. Riching KM, Mahan S, Corona CR,
1637 McDougall M, Vasta JD, Robers MB, Urh M,
1638 Daniels DL (2018) Quantitative live-cell
1639 kinetic degradation and mechanistic profiling
1640 of PROTAC mode of action. *ACS Chem Biol*
1641 13(9):2758–2770
1642
71. Chung C-I, Zhang Q, Shu X (2018) Dynamic
1643 imaging of small molecule induced protein--
1644 protein interactions in living cells with a fluo-
1645 rophore phase transition based approach. *Anal*
1646 *Chem* 90(24):14287–14293
1647
72. Kaji T, Koga H, Kuroha M, Akimoto T, Hayata
1648 K (2020) Characterization of cereblon-
1649 dependent targeted protein degrader by visual-
1650 izing the spatiotemporal ternary complex for-
1651 mation in cells. *Sci Rep* 10(1):3088
1652
73. Paiva S-L, Crews CM (2019) Targeted protein
1653 degradation: elements of PROTAC design.
1654 *Curr Opin Chem Biol* 50:111–119
1655
74. Chu T-T, Gao N, Li Q-Q, Chen P-G, Yang
1656 X-F, Chen Y-X, Zhao Y-F, Li Y-M (2016) Spe-
1657 cific knockdown of endogenous tau protein by
1658 peptide-directed ubiquitin-proteasome degra-
1659 dation. *Cell Chem Biol* 23(4):453–461
1660
75. Khan S, Zhang X, Lv D, Zhang Q, He Y,
1661 Zhang P, Liu X, Thummuri D, Yuan Y, Wie-
1662 gand JS, Pei J, Zhang W, Sharma A, McCurdy
1663 CR, Kuruvilla VM, Baran N, Ferrando AA,
1664 Kim YM, Rogojina A, Houghton PJ,
1665 Huang G, Hromas R, Konopleva M,
1666 Zheng G, Zhou D (2019) A selective
1667 BCL-XL PROTAC degrader achieves safe and
1668 potent antitumor activity. *Nat Med* 25
1669 (12):1938–1947. [https://doi.org/10.1038/](https://doi.org/10.1038/s41591-019-0668-z)
1670 [s41591-019-0668-z](https://doi.org/10.1038/s41591-019-0668-z)
1671
76. Ottis P, Toure M, Cromm PM, Ko E, Gustaf-
1672 son JL, Crews CM (2017) Assessing different
1673 E3 ligases for small molecule induced protein
1674 ubiquitination and degradation. *ACS Chem*
1675 *Biol* 12(10):2570–2578
1676
77. Kerres N, Steurer S, Schlager S, Bader G,
1677 Berger H, Caligiuri M, Dank C, Engen JR,
1678 Ettmayer P, Fischerauer B (2017) Chemically
1679 induced degradation of the oncogenic
1680

- 1681 transcription factor BCL6. *Cell Rep* 20
1682 (12):2860–2875
- 1683 78. Savitski MM, Zinn N, Faelth-Savitski M,
1684 Poeckel D, Gade S, Becher I, Muelbaier M,
1685 Wagner AJ, Strohmmer K, Werner T,
1686 Melchert S, Petretich M, Rutkowska A,
1687 Vappiani J, Franken H, Steidel M, Sweetman
1688 GM, Gilan O, Lam EYN, Dawson MA, Prinjha
1689 RK, Grandi P, Bergamini G, Bantscheff M
1690 (2018) Multiplexed proteome dynamics
1691 profiling reveals mechanisms controlling pro-
1692 tein homeostasis. *Cell* 173(1):260–274. e25
- 1693 79. Popow J, Arnhof H, Bader G, Berger H,
1694 Ciulli A, Covini D, Dank C, Gmaschitz T,
1695 Greb P, Karolyi-Özguer J, Koegl M, McCon-
1696 nell DB, Pearson M, Rieger M, Rinnenthal J,
1697 Roessler V, Schrenk A, Spina M, Steurer S,
1698 Trainor N, Traxler E, Wieshofer C,
1699 Zoepfel A, Etmayer P (2019) Highly selective
1700 PTK2 proteolysis targeting chimeras to probe
1701 focal adhesion kinase scaffolding functions. *J*
1702 *Med Chem* 62(5):2508–2520
- 1703 80. Buckley DL, Raina K, Darricarrere N, Hines J,
1704 Gustafson JL, Smith IE, Miah AH, Harling JD,
1705 Crews CM (2015) HaloPROTACS: use of
1706 small molecule PROTACs to induce degrada-
1707 tion of HaloTag fusion proteins. *ACS Chem*
1708 *Biol* 10(8):1831–1837
- 1709 81. Tovell H, Testa A, Maniaci C, Zhou H, Pre-
1710 scott AR, Macartney T, Ciulli A, Alessi DR
(2019) Rapid and reversible knockdown of
endogenously tagged endosomal proteins via
an optimized HaloPROTAC degrader. *ACS*
Chem Biol 14(5):882–892
82. Winter GE, Buckley DL, Paulk J, Roberts JM,
Souza A, Dhe-Paganon S, Bradner JE (2015)
Phthalimide conjugation as a strategy for
in vivo target protein degradation. *Science*
348(6241):1376–1381
83. Sun X, Wang J, Yao X, Zheng W, Mao Y, Lan T,
Wang L, Sun Y, Zhang X, Zhao Q, Zhao J,
Xiao RP, Zhang X, Ji G, Rao Y (2019) A chem-
ical approach for global protein knockdown
from mice to non-human primates. *Cell Discov*
5:10
84. Mullard A (2019) Arvinas's PROTACs pass
first safety and PK analysis. *Nat Rev Drug Dis-*
cov 18(12):895. [https://doi.org/10.1038/
d41573-019-00188-4](https://doi.org/10.1038/d41573-019-00188-4)
85. Nabet B, Ferguson FM, Seong BKA,
Kuljanin M, Leggett AL, Mohardt ML,
Robichaud A, Conway AS, Buckley DL, Man-
cias JD, Bradner JE, Stegmaier L, Gray
NS. (2020) Rapid and direct control of target
protein levels with VHL-recruiting dTAG
molecules *bioRxiv* 2020.03.13.980946.
[https://doi.org/10.1101/2020.03.13.
980946](https://doi.org/10.1101/2020.03.13.980946)